南須原 康行 (ナスハラ ヤスユキ)

北海道大学病院 医療安全管理部教授
Last Updated :2024/12/06

■研究者基本情報

学位

  • 医学博士, 北海道大学

Researchmap個人ページ

研究キーワード

  • 医療安全管理
  • 呼吸器内科学

研究分野

  • ライフサイエンス, 医療管理学、医療系社会学
  • ライフサイエンス, 呼吸器内科学

■経歴

経歴

  • 2017年07月 - 現在
    北海道大学病院, 医療安全管理部, 教授
  • 2008年04月 - 2017年06月
    北海道大学病院, 医療安全管理部, 准教授
  • 2005年
    - 北海道大学病院 講師
  • 2005年
    - Lecturer

学歴

  • 1988年03月 - 現在, 北海道大学医学部卒業, School of Medicine

学内役職歴

  • 北海道大学病院副病院長, 2019年4月1日 - 2022年3月31日
  • 北海道大学病院副病院長, 2022年4月1日 - 2025年3月31日

■研究活動情報

受賞

  • 2005年, ベルツ賞               
    日本国

論文

  • Associations of COVID-19 symptoms with omicron subvariants BA.2 and BA.5, host status, and clinical outcomes in Japan: a registry-based observational study.
    Sho Nakakubo, Naoki Kishida, Kenichi Okuda, Keisuke Kamada, Masami Iwama, Masaru Suzuki, Isao Yokota, Yoichi M Ito, Yasuyuki Nasuhara, Richard C Boucher, Satoshi Konno
    The Lancet. Infectious diseases, 2023年06月30日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Previous SARS-CoV-2 infection and vaccination, coupled with the rapid evolution of SARS-CoV-2 variants, have modified COVID-19 clinical manifestations. We aimed to characterise the clinical symptoms of COVID-19 individuals in omicron BA.2 and BA.5 Japanese pandemic periods to identify omicron and subvariant associations between symptoms, immune status, and clinical outcomes. METHODS: In this registry-based observational study, individuals registered in Sapporo's web-based COVID-19 information system entered 12 pre-selected symptoms, days since symptom onset, vaccination history, SARS-CoV-2 infection history, and background. Eligibility criteria included symptomatic individuals who tested positive for SARS-CoV-2 (PCR or antigen test), and individuals who were not tested for SARS-CoV-2 but developed new symptoms after a household member tested positive for SARS-CoV-2. Symptom prevalence, variables associated with symptoms, and symptoms associated with progression to severe disease were analysed. FINDINGS: Data were collected and analysed between April 25 and Sept 25, 2022. For 157 861 omicron-infected symptomatic individuals, cough was the most common symptom (99 032 [62·7%] patients), followed by sore throat (95 838 [60·7%] patients), nasal discharge (69 968 [44·3%] patients), and fever (61 218 [38·8%] patients). Omicron BA.5 infection was associated with a higher prevalence of systemic symptoms than BA.2 in vaccinated and unvaccinated individuals (adjusted odds ratio [OR] for fever: 2·18 [95% CI 2·12-2·25]). Omicron breakthrough-infected individuals with three or more vaccinations or previous infection were less likely to exhibit systemic symptoms (fever 0·50 [0·49-0·51]), but more likely to exhibit upper respiratory symptoms (sore throat 1·33 [1·29-1·36]; nasal discharge 1·84 [1·80-1·89]). Infected older individuals (≥65 years) had lower odds for all symptoms. However, when symptoms were manifest, systemic symptoms were associated with increased odds for severe disease (dyspnoea 3·01 [1·84-4·91]; fever 2·93 [1·89-4·52]), whereas upper respiratory symptoms were associated with decreased odds (sore throat 0·38 [0·24-0·63]; nasal discharge 0·48 [0·28-0·81]). INTERPRETATION: Host immunological status, omicron subvariant, and age were associated with a spectrum of COVID-19 symptoms and outcomes. BA.5 produced a higher systemic symptom prevalence than BA.2. Vaccination and previous infection reduced systemic symptom prevalence and improved outcomes but increased upper respiratory tract symptom prevalence. Systemic, but not upper respiratory, symptoms in older people heralded severe disease. Our findings could serve as a practical guide to use COVID-19 symptoms to appropriately modify health-care strategies and predict clinical outcomes for older patients with omicron infections. FUNDING: Japan Agency for Medical Research and Development.
  • Associations of COVID-19 Symptoms with Omicron Subvariants BA.2 and BA.5, Host Status, and Clinical Outcomes: A Registry-Based Observational Study in Sapporo, Japan.
    Sho Nakakubo, Naoki Kishida, Kenichi Okuda, Keisuke Kamada, Masami Iwama, Masaru Suzuki, Isao Yokota, Yoichi M Ito, Yasuyuki Nasuhara, Richard C Boucher, Satoshi Konno
    medRxiv : the preprint server for health sciences, 2023年02月07日, [国際誌]
    英語, BACKGROUND: Previous SARS-CoV-2 infection and vaccination, coupled to rapid evolution of SARS-CoV-2 variants, have modified COVID-19 clinical manifestations. We characterized clinical symptoms of COVID-19 individuals in omicron BA.2 and BA.5 Japanese pandemic periods to identify omicron and subvariant associations between symptoms, immune status, and clinical outcomes. METHODS: Individuals registered in Sapporo's web-based COVID-19 information system entered 12 pre-selected symptoms, days since symptom onset, vaccination history, SARS-CoV-2 infection history, and background. Symptom frequencies, variables associated with symptoms, and symptoms associated with progression to severe disease were analysed. RESULTS: For all omicron-infected individuals, cough was the most common symptom (62.7%), followed by sore throat (60.7%), nasal discharge (44.3%), and fever (38.8%). Omicron BA.5 infection was associated with a higher symptom burden than BA.2 in vaccinated and unvaccinated individuals. Omicron breakthrough-infected individuals with ≥ 3 vaccinations or previous infection were less likely to exhibit systemic symptoms, but more likely to exhibit upper respiratory symptoms. Infected elderly individuals had lower odds for all symptoms, but, when symptoms were manifest, systemic symptoms were associated with an increased risk, whereas upper respiratory symptoms with a decreased risk, of severe disease. CONCLUSION: Host immunological status, omicron subvariant, and age were associated with a spectrum of COVID-19 symptoms and outcomes. BA.5 produced a greater symptom burden than BA.2. Vaccination and prior infection mitigated systemic symptoms and improved outcomes, but increased upper respiratory tract symptom burden. Systemic, but not upper respiratory, symptoms in the elderly heralded severe disease.
  • C-reactive protein level predicts need for medical intervention in pregnant women with SARS-CoV2 infection: A retrospective study.
    Ryutaro Yamamoto, Hiroshi Asano, Takeshi Umazume, Masato Takaoka, Kiwamu Noshiro, Yoshihiro Saito, Kinuko Nakagawa, Kentaro Chiba, Sho Nakakubo, Yasuyuki Nasuhara, Satoshi Konno, Hidemichi Watari
    The journal of obstetrics and gynaecology research, 48, 4, 938, 945, 2022年04月, [国際誌]
    英語, 研究論文(学術雑誌), AIM: To make effective use of the limited available hospital space during the Coronavirus disease 2019 (COVID-19) pandemic, we conducted this study to investigate the laboratory indices that identify pregnant women with SARS-CoV2 infection who require medical intervention. METHODS: We carried out a retrospective analysis of pregnant women positive for COVID-19 who were admitted to Hokkaido University Hospital from September 2020 to June 2021. Medical interventions included oxygen supplementation, systemic corticosteroids, or supplemental liquids to treat infection-related symptoms. RESULTS: Forty-two infected pregnant patients were admitted to the hospital, half of whom required medical intervention (n = 21). Fever, C-reactive protein (CRP), and platelet count are all associated with need for medical intervention. Of the 32 patients with a fever of ≥37.5°C on days 0-3 after onset of syndromes, 22 (69%) continued to have a fever on days 4-6, of which 19 (86.4%) required medical intervention. CRP level on days 4-6 predicted the presence or absence of medical intervention (area under the receiver operating characteristic curve = 0.913), with a sensitivity of 81% and specificity of 100% at a CRP cutoff of 1.28 mg/dL. CONCLUSIONS: The need for medical intervention in pregnant patients can be predicted with high accuracy using a CRP cutoff of 1.28 mg/dL on days 4-6 after onset of syndromes. The presence of fever also may be an easy marker for selecting subjects who need or will need therapeutic intervention. These could be an effective triage method to determine appropriate indications for the hospitalization of pregnant women in future outbreaks.
  • Characteristics of COVID-19 patients admitted into two hospitals in sapporo, Japan: Analyses and insights from two outbreak waves.
    Takeshi Hattori, Atsushi Saito, Hirofumi Chiba, Koji Kuronuma, Masaru Amishima, Daisuke Morinaga, Yasuo Shichinohe, Yasuyuki Nasuhara, Satoshi Konno
    Respiratory investigation, 59, 2, 180, 186, 2021年03月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Coronavirus disease (COVID-19) emerged in January 2020 in Sapporo city, and the outbreak has shown two peaks. METHODS: A total of 260 COVID-19 patients were enrolled and categorized into three groups according to the pandemic pattern, jobs and situation, and disease severity. We compared clinical characteristics according to these categories. RESULTS: We found two pandemic peaks, and the proportion of patients and health providers who were infected in other hospitals had increased in the latter two periods (period 2: 49.6%, period 3: 32.7%). Particularly, the proportion of infected health providers was 27% in period 2, and they tended to be younger females with a mild condition. Severity of the disease (requirement of oxygen and/or mechanical ventilation) was associated with advanced age, and all the patients who died during admission were over 60 years old. CONCLUSIONS: We reported the temporal dynamics and characteristics of the COVID-19 pandemic in Sapporo city, Japan. This survey from the viewpoint of the hospital provides a new insight into and a better guide for the further management of the COVID-19 pandemic.
  • Implementation Status of Liver Function Tests for Monitoring Benzbromarone-Induced Hepatotoxicity: An Epidemiological Survey Using the Japanese Claims Database.
    Shungo Imai, Yasuyuki Nasuhara, Kenji Momo, Hiromitsu Oki, Hitoshi Kashiwagi, Yuki Sato, Takayuki Miyai, Mitsuru Sugawara, Yoh Takekuma
    Biological & pharmaceutical bulletin, 44, 10, 1499, 1505, 2021年, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌), A major adverse effect of benzbromarone is hepatotoxicity. Therefore, periodic liver function tests are required at least for the first 6 months of benzbromarone administration. However, it is not clear whether the relevant blood tests are implemented appropriately. Here, we performed a cross-sectional survey of the implementation status of liver function tests in patients who were newly prescribed benzbromarone, using the Japanese large claims database. Male patients who were newly prescribed benzbromarone from January 2010 to December 2016 were included. We targeted patients who continued benzbromarone during the observation period (up to 180 d from the start of administration). The primary endpoint was the proportion of patients in whom periodic liver function tests were implemented. A periodic liver function test was defined as one or more liver function tests performed during both 1-90 and 91-180 d of initial benzbromarone administration. We labeled the tests as a "periodic test" or "non-periodic test" based on whether periodic liver function tests were performed or not, respectively. Furthermore, factors influencing non-periodic test were analyzed. Periodic testing was implemented only in 28.7% of patients. Additionally, factors such as number of hospital beds ≤19 (compared to 100-199 beds) and duration of the first prescription of benzbromarone were associated with non-periodic testing. Our study revealed that periodic liver function tests are not performed sufficiently in Japan. Thus, clinicians prescribing benzbromarone should be educated about the test. Our blood-test-based approach should be applied to other drugs and countries in future research.
  • Proposal of COVID-19 Clinical Risk Score for the management of suspected COVID-19 cases: a case control study.
    Sho Nakakubo, Masaru Suzuki, Keisuke Kamada, Yu Yamashita, Junichi Nakamura, Hiroshi Horii, Kazuki Sato, Munehiro Matsumoto, Yuki Abe, Kosuke Tsuji, Nobuhisa Ishiguro, Yasuyuki Nasuhara, Satoshi Konno
    BMC infectious diseases, 20, 1, 858, 858, 2020年11月18日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: No clinical scoring system has yet been established to estimate the likelihood of coronavirus disease (COVID-19) and determine the suitability of diagnostic testing in suspected COVID-19 patients. METHODS: This was a single-center, retrospective, observational study of patients with suspected COVID-19 and confirmed COVID-19. Patient background, clinical course, laboratory and computed tomography (CT) findings, and the presence of alternative diagnoses were evaluated. Clinical risk scores were developed based on clinical differences between patients with and without COVID-19. RESULTS: Among 110 patients suspected of having COVID-19, 60.9% underwent polymerase chain reaction (PCR) testing based on the judgment of physicians. Two patients were found to have COVID-19. The clinical characteristics of 108 non-COVID-19 patients were compared with those of 23 confirmed COVID-19 patients. Patients with COVID-19 were more likely to have a history of high-risk exposures and an abnormal sense of taste and smell. The COVID-19 group had significantly higher rates of subnormal white blood cell counts, lower eosinophil counts, and lower procalcitonin levels than the non-COVID-19 group. When blood test results, CT findings, and the presence of alternative diagnoses were scored on an 11-point scale (i.e., "COVID-19 Clinical Risk Score"), the COVID-19 group scored significantly higher than the non-COVID-19 group, more than four points in the COVID-19 group. All non-COVID patients who did not undergo PCR had a score of 4 or less. CONCLUSIONS: The COVID-19 Clinical Risk Score may enable the risk classification of patients suspected of having COVID-19 and can help in decision-making in clinical practice, including appropriateness of diagnostic testing. Further studies and prospective validation with an increased sample size are required.
  • Older age is associated with sustained detection of SARS-CoV-2 in nasopharyngeal swab samples.
    Takeshi Hattori, Masaru Amishima, Daisuke Morinaga, Keisuke Kamada, Sho Nakakubo, Yu Yamashita, Yasuo Shichinohe, Shinichi Fujisawa, Mutsumi Nishida, Yasuyuki Nasuhara, Takanori Teshima, Satoshi Konno
    The Journal of infection, 82, 1, 159, 198, 2020年06月21日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Analysis of the Implementation of Blood Tests Specified in the Package Insert After Prescription of Thiamazole.
    Yasuyuki Nasuhara, Ken Sakushima, Hiromitsu Oki, Takehiro Yamada, Ken Iseki, Reona Umeki, Akira Endoh
    Journal of patient safety, 16, 1, 24, 29, 2020年03月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), OBJECTIVES: The antithyroid drug thiamazole has long been known to cause the serious adverse effect of agranulocytosis, and performing regular blood tests is listed among the warnings on the package insert. We conducted a retrospective survey of how often doctors conducted blood tests in accordance with the package insert when thiamazole was prescribed at our hospital. METHODS: The subjects were patients to whom thiamazole was newly prescribed at our hospital between April 2004 and March 2012. During the target period, thiamazole was newly prescribed to 438 patients. RESULTS: We found that blood tests after prescription of thiamazole as listed in the warning section on the package insert are not performed sufficiently. The rate at which white blood cell counts were obtained decreased over time. The rate at which differential leukocyte counts were obtained was approximately 80% of white blood cell counts at all observational time points. In contrast, the percentage of subjects whose white blood cell counts were measured increased according to a time-trend analysis. CONCLUSIONS: This study revealed that blood tests after prescription of thiamazole as listed in the warning section on the package insert are not performed sufficiently at our hospital. The rate at which differential leukocyte counts were obtained was approximately 80% of white blood cell counts at all observational periods. Physician education should be more rigorously performed than presently done, and automatic generation of warnings that urge blood tests and patient education regarding the importance of blood tests is also important.
  • Rapidly progressive organizing pneumonia associated with COVID-19.
    Hiroshi Horii, Keisuke Kamada, Sho Nakakubo, Yu Yamashita, Junichi Nakamura, Yasuyuki Nasuhara, Satoshi Konno
    Respiratory medicine case reports, 31, 101295, 101295, 2020年, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), We report a case of clinically diagnosed secondary organizing pneumonia (SOP) associated with coronavirus disease 2019 (COVID-19). A 70-year-old woman who had been diagnosed with COVID-19 was admitted to Hokkaido University Hospital. Although her fever, cough, dyspnea, and serum C-reactive protein levels improved, she developed rapidly progressive respiratory failure and computed tomography revealed the development of bilateral lung consolidation. Her dyspnea was relieved, and her oxygenation levels and radiological findings improved after commencing corticosteroid treatment. Blood biomarkers for interstitial lung disease, Krebs von den Lungen-6 (KL-6) and surfactant protein D (SP-D), showed different responses during the clinical course of her disease. Evaluation of serial changes in levels of KL-6 and SP-D may help diagnose and monitor COVID-19-associated organizing pneumonia (OP). Clinicians should be aware that SOP can develop in response to COVID-19 and that these patients may benefit from the use of steroids.
  • Unique Mortality Profile in Japanese Patients with COPD: An Analysis from the Hokkaido COPD Cohort Study.
    Hironi Makita, Masaru Suzuki, Satoshi Konno, Kaoruko Shimizu, Yasuyuki Nasuhara, Katsura Nagai, Yasushi Akiyama, Satoshi Fuke, Hiroshi Saito, Takeshi Igarashi, Kimihiro Takeyabu, Masaharu Nishimura
    International journal of chronic obstructive pulmonary disease, 15, 2081, 2090, 2020年, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Purpose: Causes of death may be unique and different in Japanese patients with COPD because they are generally older, thinner, experience fewer exacerbations, and live longer than those in other countries. We investigated the detailed mortality profile in the Hokkaido COPD cohort study, which completed a 10-year follow-up with a very low dropout rate. Patients and Methods: We prospectively examined the 10-year natural history in 279 Japanese patients with COPD (GOLD 1, 26%; GOLD 2, 45%; GOLD 3, 24%; and GOLD 4, 5%). The majority of patients were male, and the average age at baseline was 69 years old. About 95% of all patients had accurate mortality data. The risk factors for mortality were also analyzed. Results: During the 10 years, 112 patients (40%) died. Their median survival time was 6.1 years (interquartile range: 4.7-7.9 years), and age at death was 79 ± 6 years old (mean ± SD). Respiratory diseases, including pneumonia, were the leading causes of death in 45 (40%), followed by lung cancer in 24 (21%), other cancers in 18 (16%), and cardiovascular diseases in 12 (11%). In particular, lung cancer-related death was equally distributed across all COPD stages, with a higher proportion of lung cancer in the relatively younger generation (<64 years old). Older age at baseline, lower BMI, and severer emphysema were significant risk factors for all-cause mortality. Conclusion: The unique mortality profile observed in this study should be considered when designing strategies for the management of patients with COPD in any geographic region.
  • Venipuncture Nerve Injuries in the Upper Extremity From More Than 1 Million Procedures.
    Yukinori Tsukuda, Tadanao Funakoshi, Yasuyuki Nasuhara, Yusuke Nagano, Chikara Shimizu, Norimasa Iwasaki
    Journal of patient safety, 15, 4, 299, 301, 2019年12月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), OBJECTIVES: The purpose of this study was to investigate the nerve injury rate for 1 million venipunctures and the efficacy of attempts to avoid severe nerve injury. METHODS: We collected data for outpatients from whom a venipuncture blood sample was obtained in our hospital from 2005 to 2014. Every venipuncture procedure for outpatients was performed by a trained nurse or clinical technologist at the center for blood sampling in our hospital. In addition, a series of lectures by a specialist is held in our hospital at various times. All complaints related to venipuncture blood sampling were reported to our division of hospital safety management and were followed up using the guidelines for injuries related to the venipuncture. RESULTS: The number of venipuncture-related complications was 293 (0.027%, 1/3700) of 1,082,053 during the 10 years. A total of 40 of the 1,082,053 venipunctures were referred to the department of orthopedic surgery, and 16 (0.0015%, 1/67,000) were diagnosed with obvious nerve injuries. The average duration of the treatment was 46.4 days (range, 1-126 days); 69% of the patients recovered within 5 weeks, and all patients recovered within 18 weeks. CONCLUSIONS: Although it is impossible to completely prevent venipuncture-related complications, appropriate venipuncture skills and risk management decrease the incidence of chronic or permanent nerve injury risk after venipuncture.
  • Annual change in FEV1 in elderly 10-year survivors with established chronic obstructive pulmonary disease.
    Suzuki M, Makita H, Konno S, Shimizu K, Nasuhara Y, Nagai K, Akiyama Y, Fuke S, Saito H, Igarashi T, Takeyabu K, Nishimura M
    Scientific reports, 9, 1, 2073, 2073, 2019年02月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Long-term decline in lung function is generally considered to be progressive in individuals with established chronic obstructive pulmonary disease (COPD), despite the presence of intersubject variation. We hypothesized that the annualized rate of decline in forced expiratory volume in 1 second (FEV1) would not be constant among different time periods in the natural history of established COPD. We compared the annual change rates in FEV1 during the first 5 years and the last 5 years, estimated separately using a linear mixed-effects model in 10-year survivors (n = 110). The subjects were classified into three FEV1 decline groups, based on the 25th and 75th percentile values in each time period. The rates of FEV1 changes, calculated from the first 5 years and the last 5 years, did not correlate with each other among 10-year survivors; the subjects of each FEV1 decline group during the first 5 years did not consistently remain in the same FEV1 decline group during the last 5 years. Smoking status and exacerbation frequency were not associated with decline in FEV1. In conclusion, the disease activity, which is often expressed as annualized change in FEV1, might be changeable either way over years in patients with established COPD.
  • A Semiquantitative Computed Tomographic Grading System for Evaluating Therapeutic Response in Pulmonary Alveolar Proteinosis.
    Sayoko Tokura, Masanori Akira, Tomohisa Okuma, Ryushi Tazawa, Toru Arai, Chikatoshi Sugimoto, Akiko Matsumuro, Masaki Hirose, Toshinori Takada, Koh Nakata, Haruyuki Ishii, Yasunori Kasahara, Masayuki Hojo, Shinya Ohkouchi, Yoshiko Tsuchihashi, Masanori Yokoba, Ryosuke Eda, Hideaki Nakayama, Takahito Nei, Konosuke Morimoto, Yasuyuki Nasuhara, Masahito Ebina, Toshio Ichiwata, Koichiro Tatsumi, Etsuro Yamaguchi, Yoshikazu Inoue
    Annals of the American Thoracic Society, 14, 9, 1403, 1411, 2017年09月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), RATIONALE: A useful semiquantitative method of using computed tomographic (CT) images to evaluate therapeutic response in pulmonary alveolar proteinosis (PAP) has not been established, although the extent score or grading score of ground-glass opacities has been used. OBJECTIVES: The purpose of this study was to establish a semiquantitative method for evaluating therapeutic response in PAP. METHODS: CT scans were obtained within 1 month before and after therapy from 32 patients with PAP who participated in a multicenter phase II trial of granulocyte-macrophage colony-stimulating factor inhalation therapy. The scans were evaluated by two chest radiologists independently. Increased parenchymal opacity was evaluated on the basis of its intensity and extent (CT grade), and the severity scores were compared with CT scores based on the extent alone (CT extent), as well as on the basis of physiological and serological results. RESULTS: CT grade score and CT extent score had significant correlation with diffusing capacity of the lung for carbon monoxide percent predicted (%DlCO), PaO2, VC percent predicted (%VC), Krebs von den Lungen (KL)-6, and surfactant protein D. The change in CT grade score between pre- and post-treatment examinations (ΔCT grade) correlated better with difference of PaO2 between pre- and post-treatment examinations (ΔPaO2) than ΔCT extent (difference of CT extent score between pre- and post-treatment examinations). In univariate analysis, ΔCT grade, ΔCT extent, ΔKL-6, Δ%DlCO, Δ%VC, and change in surfactant protein D correlated significantly with ΔPaO2. In multivariate analysis, ΔCT grade and ΔKL-6 correlated more closely with ΔPaO2. CONCLUSIONS: Although a number of CT variables were collected, the currently proposed grading system that correlates well with PaO2 should be viewed as a retrospective scoring system that needs future validation with another PAP cohort.
  • Characteristics of Medical Adverse Events/Near Misses Associated With Laparoscopic/Thoracoscopic Surgery: A Retrospective Study Based on the Japanese National Database of Medical Adverse Events.
    Abe T, Murai S, Nasuhara Y, Shinohara N
    Journal of patient safety, 15, 4, 343, 351, 2017年09月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), OBJECTIVES: The aim of this study was to clarify the characteristics of adverse events/near misses during laparoscopic/thoracoscopic surgery. METHODS: Using relevant key words for minimally invasive surgeries, 540 records were identified in the database of the Japan Council for Quality Health Care. After data review and the classification of adverse events, 746 events associated with laparoscopic (laparo group) and/or thoracoscopic (thoraco group) surgery were identified. We calculated the frequency of each event, compared the frequency regarding recurrent events, and evaluated the types of event that had resulted in deaths between the 2 groups. RESULTS: There were 582 events in the laparo group, 159 in the thoraco group, and 5 in those undergoing combined surgery. Overall, injury of other organs (11.4%, 85/746), retention of a foreign body (9.1%, 68/746), breakage/failure of medical equipment or devices (6.2%, 46/746), massive bleeding (5.9%, 44/746), misperception of anatomy (5.6%, 42/746), and vascular injury (4.8%, 36/746) were frequently reported. There were marked differences in the frequency of injury of other organs (laparo group: 13.4%, 78/582; thoraco group: 4.4%, 7/159), massive bleeding (laparo group: 3.4%, 20/582; thoraco group: 14.5%, 23/159), and vascular injury (laparo group: 2.6%, 15/582; thoraco group: 12.6%, 20/159) between the 2 groups. Among the 56 patient-death reports, 132 adverse events were identified. In the thoraco group, bleeding events were frequently observed, whereas in the laparo group, various categories of events were noted. CONCLUSIONS: We observed recurrent incidents and differences in the frequency between the 2 groups. Surgeons should keep in mind these characteristics. Retention of a foreign body and the breakage/malfunctioning of instruments might be reduced by the introduction of specialized checklists.
  • 医療安全管理者が求める安全性の確立していない医薬品の使用について               
    南須原 康行
    医薬ジャーナル, 53, 2485, 2490, 2017年, [査読有り], [招待有り]
    日本語, 研究論文(学術雑誌)
  • Erratum to: Physicians' responses to computerized drug interaction alerts with password overrides.
    Yasuyuki Nasuhara, Ken Sakushima, Akira Endoh, Reona Umeki, Hiromitsu Oki, Takehiro Yamada, Ken Iseki, Makoto Ishikawa
    BMC medical informatics and decision making, 16, 1, 108, 108, BIOMED CENTRAL LTD, 2016年08月10日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Background: Although evidence has suggested that computerized drug-drug interaction alert systems may reduce the occurrence of drug-drug interactions, the numerous reminders and alerts generated by such systems could represent an excessive burden for clinicians, resulting in a high override rate of not only unimportant, but also important alerts.
    Methods: We analyzed physicians' responses to alerts of relative contraindications and contraindications for coadministration in a computerized drug-drug interaction alert system at Hokkaido University Hospital. In this system, the physician must enter a password to override an alert and continue an order. All of the drug-drug interaction alerts generated between December 2011 and November 2012 at Hokkaido University Hospital were included in this study.
    Results: The system generated a total of 170 alerts of relative contraindications and contraindication for coadministration; 59 (34.7 %) of the corresponding orders were cancelled after the alert was accepted, and 111 (65.3 %) were overridden. The most frequent contraindication alert was for the combination of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors and fibrates. No incidents involving drug-drug interactions were reported among patients who were prescribed contraindicated drug pairs after an override.
    Conclusions: Although computerized drug-drug interaction alert systems that require password overrides appear useful for promoting medication safety, having to enter passwords to override alerts may represent an excessive burden for the prescribing physician. Therefore, both patient safety and physicians' workloads should be taken into consideration in future designs of computerized drug-drug interaction alert systems.
  • 【特発性間質性肺炎の最前線】分子サイズと肺胞 血液間動態が血清KL-6値に与える影響
    重村 雅彦, 今野 哲, 南須原 康行, 西村 正治
    呼吸器内科, 30, 2, 118, 123, (有)科学評論社, 2016年08月, [査読有り]
    日本語, 研究論文(学術雑誌)
  • Three-day regimen of oseltamivir for postexposure prophylaxis of influenza in wards
    Ishiguro N., Oyamada R., Nasuhara Y., Yamada T., Miyamoto T., Imai S., Akizawa K., Fukumoto T., Iwasaki S., Iijima H., Ono K.
    Journal of Hospital Infection, 94, 2, 150, 153, Elsevier, 2016年, [査読有り]
    英語, 研究論文(学術雑誌), Inpatients who had been in close contact with patients with influenza were given oseltamivir [75 mg capsules once daily for adults or 2 mg/kg (maximum of 75 mg) once daily for children] for three days as postexposure prophylaxis (PEP). The index patients with influenza were prescribed a neuraminidase inhibitor and were discharged immediately or transferred to isolation rooms. The protective efficacy of oseltamivir for three days was 93% overall [95% confidence interval (CI) 53-99%; P = 0.023] and 94% for influenza A (95% CI 61-99%; P = 0.017), which is comparable to that of seven- to 10-day regimens of oseltamivir as PEP.
  • Physicians' responses to computerized drug interaction alerts with password overrides.
    Yasuyuki Nasuhara, Ken Sakushima, Akira Endoh, Reona Umeki, Hiromitsu Oki, Takehiro Yamada, Ken Iseki, Makoto Ishikawa
    BMC medical informatics and decision making, 15, 74, 74, 2015年08月28日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Although evidence has suggested that computerized drug-drug interaction alert systems may reduce the occurrence of drug-drug interactions, the numerous reminders and alerts generated by such systems could represent an excessive burden for clinicians, resulting in a high override rate of not only unimportant, but also important alerts. METHODS: We analyzed physicians' responses to alerts of relative contraindications and contraindications for coadministration in a computerized drug-drug interaction alert system at Hokkaido University Hospital. In this system, the physician must enter a password to override an alert and continue an order. All of the drug-drug interaction alerts generated between December 2011 and November 2012 at Hokkaido University Hospital were included in this study. RESULTS: The system generated a total of 170 alerts of relative contraindications and contraindication for coadministration; 59 (34.7 %) of the corresponding orders were cancelled after the alert was accepted, and 111 (65.3 %) were overridden. The most frequent contraindication alert was for the combination of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors and fibrates. No incidents involving drug-drug interactions were reported among patients who were prescribed contraindicated drug pairs after an override. CONCLUSIONS: Although computerized drug-drug interaction alert systems that require password overrides appear useful for promoting medication safety, having to enter passwords to override alerts may represent an excessive burden for the prescribing physician. Therefore, both patient safety and physicians' workloads should be taken into consideration in future designs of computerized drug-drug interaction alert systems.
  • Time trend of injection drug errors before and after implementation of bar-code verification system.
    Ken Sakushima, Reona Umeki, Akira Endoh, Yoichi M Ito, Yasuyuki Nasuhara
    Technology and health care : official journal of the European Society for Engineering and Medicine, 23, 3, 267, 74, 2015年, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Bar-code technology, used for verification of patients and their medication, could prevent medication errors in clinical practice. OBJECTIVE: Retrospective analysis of electronically stored medical error reports was conducted in a university hospital. METHODS: The number of reported medication errors of injected drugs, including wrong drug administration and administration to the wrong patient, was compared before and after implementation of the bar-code verification system for inpatient care. RESULTS: A total of 2867 error reports associated with injection drugs were extracted. Wrong patient errors decreased significantly after implementation of the bar-code verification system (17.4/year vs. 4.5/year, p< 0.05), although wrong drug errors did not decrease sufficiently (24.2/year vs. 20.3/year). The source of medication errors due to wrong drugs was drug preparation in hospital wards. CONCLUSION: Bar-code medication administration is effective for prevention of wrong patient errors. However, ordinary bar-code verification systems are limited in their ability to prevent incorrect drug preparation in hospital wards.
  • Analysis of the implementation of blood tests specified in the drug package insert after prescription of thiamazole
    NASUHARA Yasuyuki
    Journal of Patient Safety, Epub, 2015年, [査読有り]
    英語, 研究論文(学術雑誌)
  • Duration of benefit in patients with autoimmune pulmonary alveolar proteinosis after inhaled granulocyte-macrophage colony-stimulating factor therapy.
    Ryushi Tazawa, Yoshikazu Inoue, Toru Arai, Toshinori Takada, Yasunori Kasahara, Masayuki Hojo, Shinya Ohkouchi, Yoshiko Tsuchihashi, Masanori Yokoba, Ryosuke Eda, Hideaki Nakayama, Haruyuki Ishii, Takahito Nei, Konosuke Morimoto, Yasuyuki Nasuhara, Masahito Ebina, Masanori Akira, Toshio Ichiwata, Koichiro Tatsumi, Etsuro Yamaguchi, Koh Nakata
    Chest, 145, 4, 729, 737, 2014年04月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Treatment of autoimmune pulmonary alveolar proteinosis (aPAP) by subcutaneous injection or inhaled therapy of granulocyte-macrophage colony-stimulating factor (GM-CSF) has been demonstrated to be safe and efficacious in several reports. However, some reports of subcutaneous injection described transient benefit in most instances. The durability of response to inhaled GM-CSF therapy is not well characterized. METHODS: To elucidate the risk factors for recurrence of aPAP after GM-CSF inhalation, 35 patients were followed up, monitoring for the use of any additional PAP therapies and disease severity score every 6 months. Physiologic, serologic, and radiologic features of the patients were analyzed for the findings of 30-month observation after the end of inhalation therapy. RESULTS: During the observation, 23 patients remained free from additional treatments, and twelve patients required additional treatments. There were no significant differences in age, sex, symptoms, oxygenation indexes, or anti-GM-CSF antibody levels at the beginning of treatment between the two groups. Baseline vital capacity (% predicted, %VC) were higher among those who required additional treatment (P<.01). Those patients not requiring additional treatment maintained the improved disease severity score initially achieved. A significant difference in the time to additional treatment between the high %VC group (%VC≥80.5) and the low %VC group was seen by a Kaplan-Meier analysis and a log-rank test (P<.0005). CONCLUSIONS: These results demonstrate that inhaled GM-CSF therapy sustained remission of aPAP in more than one-half of cases, and baseline %VC might be a prognostic factor for disease recurrence. TRIAL REGISTRY: ISRCTN Register and JMACCT Clinical Trial Registry; No.: ISRCTN18931678 and JMAIIA00013; URL: http://www.isrctn.org and http://www.jmacct.med.or.jp.
  • Serum KL-6 concentrations are associated with molecular sizes and efflux behavior of KL-6/MUC1 in healthy subjects.
    Shigemura M, Konno S, Nasuhara Y, Shijubo N, Shimizu C, Nishimura M
    Clinica chimica acta; international journal of clinical chemistry, 424, 148, 152, 2013年09月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Occupational and environmental impact on the clinical course of autoimmune pulmonary alveolar proteinosis
    Yoshikazu Inoue, Koh Nakata, Toru Arai, Etsuro Yamaguchi, Toshio Ichiwata, Masahito Ebina, Ryushi Tazawa, Haruyuki Ishii, Yasuhiro Setoguchi, Masanori Kitaichi, Masanori Akira, Koichiro Tatsumi, Yasuyuki Nasuhara, Kazutoshi Cho, Yoshiko Tsuchihashi, Kanji Uchida, Toshinori Takada, Hideaki Nakayama, Keisuke Tomii, Chikatoshi Sugimoto, Yasuo Kohashi, Shinya Ohkouchi, Yasunori Kasahara, Kohnosuke Morimoto, Naoko Sakamoto
    EUROPEAN RESPIRATORY JOURNAL, 40, EUROPEAN RESPIRATORY SOC JOURNALS LTD, 2012年09月, [査読有り]
    英語
  • Impact of asthmatic control status on serum cystatin C concentrations.
    Shigemura M, Konno S, Nasuhara Y, Shimizu C, Matsuno K, Nishimura M
    Clinical chemistry and laboratory medicine : CCLM / FESCC, 50, 1367, 1371, 8, 2012年08月, [査読有り]
  • Effects of molecular structural variants on serum Krebs von den Lungen-6 levels in sarcoidosis.
    Shigemura M, Nasuhara Y, Konno S, Shimizu C, Matsuno K, Yamguchi E, Nishimura M
    Journal of translational medicine, 10, 111, 111, BioMed Central, 2012年07月, [査読有り]
    英語, 研究論文(学術雑誌), Background: Serum Krebs von den Lungen-6 (KL-6), which is classified as human mucin-1 (MUC1), is used as a marker of sarcoidosis and other interstitial lung diseases. However, there remain some limitations due to a lack of information on the factors contributing to increased levels of serum KL-6. This study was designed to investigate the factors contributing to increased levels of serum KL-6 by molecular analysis. Methods: Western blot analysis using anti-KL-6 antibody was performed simultaneously on the bronchoalveolar lavage fluid (BALF) and serum obtained from 128 subjects with sarcoidosis. Results: KL-6/MUC1 in BALF showed three bands and five band patterns. These band patterns were associated with the MUC1 genotype and the KL-6 levels. KL-6/MUC1 band patterns in serum were dependent on molecular size class in BALF. Significantly increased levels of serum KL-6, serum/BALF KL-6 ratio and serum soluble interleukin 2 receptor were observed in the subjects with influx of high molecular size KL-6/MUC1 from the alveoli to blood circulation. The multivariate linear regression analysis involving potentially relevant variables such as age, gender, smoking status, lung parenchymal involvement based on radiographical stage and molecular size of KL-6/MUC1 in serum showed that the molecular size of KL-6/MUC1 in serum was significant independent determinant of serum KL-6 levels. Conclusions: The molecular structural variants of KL-6/MUC1 and its leakage behavior affect serum levels of KL-6 in sarcoidosis. This information may assist in the interpretation of serum KL-6 levels in sarcoidosis.
  • Reduced GM-CSF autoantibody in improved lung of autoimmune pulmonary alveolar proteinosis
    K. Ohashi, A. Sato, T. Takada, T. Arai, Y. Kasahara, M. Hojo, T. Nei, H. Nakayama, N. Motoi, S. Urano, R. Eda, M. Yokoba, Y. Tsuchihashi, Y. Nasuhara, H. Ishii, M. Ebina, E. Yamaguchi, Y. Inoue, K. Nakata, R. Tazawa
    European Respiratory Journal, 39, 3, 777, 780, European Respiratory Society, 2012年03月01日, [査読有り]
    英語
  • Endobronchial ultrasonography with a guide sheath in the diagnosis of benign peripheral diseases.
    Shinagawa N, Nakano K, Asahina H, Kikuchi E, Ito T, Matsuno Y, Oizumi S, Nasuhara Y, Nishimura M
    The Annals of thoracic surgery, 93, 3, 951, 957, 2012年03月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Direct evidence that GM-CSF inhalation improves lung clearance in pulmonary alveolar proteinosis.
    Kazumasa Ohashi, Atsuyasu Sato, Toshinori Takada, Toru Arai, Takahito Nei, Yasunori Kasahara, Natsuki Motoi, Masayuki Hojo, Shinya Urano, Haruyuki Ishii, Masanori Yokoba, Ryosuke Eda, Hideaki Nakayama, Yasuyuki Nasuhara, Yoshiko Tsuchihashi, Chinatsu Kaneko, Hiroko Kanazawa, Masahito Ebina, Etsuro Yamaguchi, Jacqueline Kirchner, Yoshikazu Inoue, Koh Nakata, Ryushi Tazawa
    Respiratory medicine, 106, 2, 284, 93, 2012年02月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Autoimmune pulmonary alveolar proteinosis (aPAP) is caused by granulocyte/macrophage-colony stimulating factor (GM-CSF) autoantibodies in the lung. Previously, we reported that GM-CSF inhalation therapy improved alveolar-arterial oxygen difference and serum biomarkers of disease severity in these patients. It is plausible that inhaled GM-CSF improves the dysfunction of alveolar macrophages and promotes the clearance of the surfactant. However, effect of the therapy on components in bronchoalveolar lavage fluid (BALF) remains unclear. OBJECTIVES: To figure out changes in surfactant clearance during GM-CSF inhalation therapy. METHODS: We performed retrospective analyses of BALF obtained under a standardized protocol from the same bronchus in each of 19 aPAP patients before and after GM-CSF inhalation therapy (ISRCTN18931678, JMA-IIA00013; total dose 10.5-21 mg, duration 12-24 weeks). For evaluation, the participants were divided into two groups, high responders with improvement in alveolar-arterial oxygen difference ≥13 mmHg (n = 10) and low responders with that < 13 mmHg (n = 9). RESULTS: Counts of both total cells and alveolar macrophages in BALF did not increase during the therapy. However, total protein and surfactant protein-A (SP-A) were significantly decreased in high responders, but not in low responders, suggesting that clearance of surfactant materials is correlated with the efficacy of the therapy. Among 94 biomarkers screened in bronchoalveolar lavage fluid, we found that the concentration of interleukin-17 and cancer antigen-125 were significantly increased after GM-CSF inhalation treatment. CONCLUSIONS: GM-CSF inhalation decreased the concentration of total protein and SP-A in BALF, and increase interleukin-17 and cancer antigen-125 in improved lung of autoimmune pulmonary alveolar proteinosis.
  • Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease.
    Nishimura M, Makita H, Nagai K, Konno S, Nasuhara Y, Hasegawa M, Shimizu K, Betsuyaku T, Ito YM, Fuke S, Igarashi T, Akiyama Y, Ogura S, Hokkaido COPD Cohort, Study Investigators
    American journal of respiratory and critical care medicine, 185, 1, 44, 52, 1, 2012年01月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), RATIONALE: Although the rate of annual decline in FEV1 is one of the most important outcome measures in chronic obstructive pulmonary disease (COPD), little is known about intersubject variability based on clinical phenotypes. OBJECTIVES: To examine the intersubject variability in a 5-year observational cohort study, particularly focusing on emphysema severity. METHODS: A total of 279 eligible patients with COPD (stages I-IV: 26, 45, 24, and 5%) participated. We conducted a detailed assessment of pulmonary function and computed tomography (CT) at baseline, and performed spirometry every 6 months before and after inhalation of bronchodilator. Smoking status, exacerbation, and pharmacotherapy were carefully monitored. Emphysema severity was evaluated by CT and annual measurements of carbon monoxide transfer coefficient. MEASUREMENTS AND MAIN RESULTS: Using mixed effects model analysis, the annual decline in post-bronchodilator FEV1 was -32±24 (SD) ml/yr (n=261). We classified the subjects of less than the 25th percentile as Rapid decliners, the 25th to 75th percentile as Slow decliners, and greater than the 75th percentile as Sustainers (-63±2, -31±1, and -2±1 [SE] ml/yr). Emphysema severity, but not %FEV1, showed significant differences among the three groups. Multiple logistic regression analysis demonstrated that the Rapid decliners were independently associated with emphysema severity assessed either by CT or carbon monoxide transfer coefficient. The Sustainers displayed less emphysema and higher levels of circulating eosinophils. CONCLUSIONS: Emphysema severity is independently associated with a rapid annual decline in FEV1 in COPD. Sustainers and Rapid decliners warrant specific attention in clinical practice.
  • [A case of multifocal micronodular pneumocyte hyperplasia without clinical findings of tuberous sclerosis].
    Natsuko Taniguchi, Satoshi Konno, Yasuyuki Nasuhara, Yoshihiro Matsuno, Teruaki Oka, Masaharu Nishimura
    Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society, 49, 5, 355, 9, 2011年05月, [査読有り], [国内誌]
    日本語, 研究論文(学術雑誌), A 30-year-old woman was referred because of multiple ground-glass opacities (GGOs) on chest CT examination. Lung biopsy was performed. Histologically, multifocal well-demarcated nodular lesions comprising proliferation of type II pneumocytes with mild fibrous thickening of the alveolar septa were observed in the lung tissue. We made a histopathologic diagnosis of multifocal micronodular pneumocyte hyperplasia (MMPH). Neither the clinical findings nor the family history of the patient suggested tuberous sclerosis (TSC). MMPH is a pulmonary manifestation of tuberous sclerosis, together with lymphangioleiomyomatosis (LAM). MMPH should be considered as a differential diagnosis of multiple GGOs in the lung even when findings of TSC and LAM are not recognized.
  • Inhaled granulocyte/macrophage-colony stimulating factor as therapy for pulmonary alveolar proteinosis.
    Tazawa R, Trapnell BC, Inoue Y, Arai T, Takada T, Nasuhara Y, Hizawa N, Kasahara Y, Tatsumi K, Hojo M, Ishii H, Yokoba M, Tanaka N, Yamaguchi E, Eda R, Tsuchihashi Y, Morimoto K, Akira M, Terada M, Otsuka J, Ebina M, Kaneko C, Nukiwa T, Krischer JP, Akazawa K, Nakata K
    American journal of respiratory and critical care medicine, 181, 12, 1345, 1354, 12, 2010年06月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), RATIONALE: Inhaled granulocyte/macrophage-colony stimulating factor (GM-CSF) is a promising therapy for pulmonary alveolar proteinosis (PAP) but has not been adequately studied. OBJECTIVES: To evaluate safety and efficacy of inhaled GM-CSF in patients with unremitting or progressive PAP. METHODS: We conducted a national, multicenter, self-controlled, phase II trial at nine pulmonary centers throughout Japan. Patients who had lung biopsy or cytology findings diagnostic of PAP, an elevated serum GM-CSF antibody level, and a Pa(O(2)) of less than 75 mm Hg entered a 12-week observation period. Those who improved (i.e., alveolar-arterial oxygen difference [A-aDO(2)] decreased by 10 mm Hg) during observation were excluded. The rest entered sequential periods of high-dose therapy (250 microg Days 1-8, none Days 9-14; x six cycles; 12 wk); low-dose therapy (125 microg Days 1-4, none Days 5-14; x six cycles; 12 wk), and follow-up (52 wk). MEASUREMENTS AND MAIN RESULTS: Fifty patients with PAP were enrolled in the study. During observation, nine improved and two withdrew; all of these were excluded. Of 35 patients completing the high- and low-dose therapy, 24 improved, resulting in an overall response rate of 62% (24/39; intention-to-treat analysis) and reduction in A-aDO(2) of 12.3 mm Hg (95% confidence interval, 8.4-16.2; n = 35, P < 0.001). No serious adverse events occurred, and serum GM-CSF autoantibody levels were unchanged. A treatment-emergent correlation occurred between A-aDO(2) and diffusing capacity of the lung, and high-resolution CT revealed improvement of ground-glass opacity. Twenty-nine of 35 patients remained stable without further therapy for 1 year. CONCLUSIONS: Inhaled GM-CSF therapy is safe, effective, and provides a sustained therapeutic effect in autoimmune PAP. Clinical trial registered with www.controlled-trials.com/isrctn (ISRCTN18931678), www.jmacct.med.or.jp/english (JMA-IIA00013).
  • [Intravascular large B-cell lymphoma with massive pulmonary lesions].
    Asumi Higashiyama, Satoshi Hashino, Masahiro Onozawa, Mutsumi Takahata, Kohei Okada, Kaoru Kahata, Natsuko Taniguchi, Yasuyuki Nasuhara, Kanako Kubota, Nozomu Fujimoto, Yoshihiro Matsuno, Masahiro Nishimura, Masahiro Asaka
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 51, 5, 353, 6, 2010年05月, [査読有り], [国内誌]
    日本語, 研究論文(学術雑誌), A 61-year-old man was admitted to our hospital with dyspnea on effort. Neither computed tomography scan nor chest X-ray film detected any specific findings that could explain hypoxemia. Since (67)Ga scintigraphy showed abnormal uptake in the bilateral lungs, transbronchial lung biopsy (TBLB) was performed. The TBLB specimen was diagnosed as intravascular large B-cell lymphoma (IVLBCL). There was no involvement of any other organ considered typical of IVLBCL. In cases showing clinical findings such as hypoxia despite mild pulmonary radiographic changes, a definitive diagnosis should be made using methods such as TBLB with consideration given to the possibility of IVLBCL.
  • Levels of transferrin in bronchoalveolar lavage fluid in sarcoidosis.
    Shigemura M, Nasuhara Y, Konno S, Hattori T, Shimizu C, Matsuno K, Nishimura M
    Lung, 188, 2, 151, 157, 2, 2010年04月, [査読有り]
    英語, There has been only one report showing high levels of transferrin (Tf) in bronchoalveolar lavage fluid (BALF) in patients with sarcoidosis. The aim of this study is to assess the levels of Tf in both BALF and serum and to examine the relationship between the levels of Tf and other disease markers in sarcoidosis. Subjects were 64 sarcoidosis and 10 healthy controls. Tf in BALF and serum was measured by nephelometric assay. Median Tf levels in BALF from sarcoidosis was 0.70 mg/dl (range, 0.00-3.97), which was significantly higher when compared with controls (0.36 mg/dl; range, 0.00-1.02) (p = 0.005). In contrast, median Tf levels in serum from sarcoidosis was 258 mg/dl (range, 171-383), which was significantly lower when compared with controls (322 mg/dl; range, 234-356) (p = 0.003). Tf levels in BALF were significantly correlated with both the percentage of lymphocytes (r = 0.617, p = 0.001) and serum angiotensin-converting enzyme activity (r = 0.363, p = 0.003) and serum soluble interleukin-2 receptor (r = 0.450, p = 0.001) in sarcoidosis. Levels of Tf in BALF from patients with sarcoidosis were not influenced by smoking status. The levels of Tf in sarcoidosis are high in BALF, but low in serum. Increased levels of Tf in BALF may reflect the disease activity.
  • Aging enhances susceptibility to cigarette smoke-induced inflammation through bronchiolar chemokines.
    Chinatsu Moriyama, Tomoko Betsuyaku, Yoko Ito, Ichiro Hamamura, Junko Hata, Hiroshi Takahashi, Yasuyuki Nasuhara, Masaharu Nishimura
    American journal of respiratory cell and molecular biology, 42, 3, 304, 11, 2010年03月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Cigarette smoking and aging are major risk factors for chronic obstructive pulmonary disease. An unsolved question is whether elderly lungs are particularly vulnerable to cigarette smoke (CS) exposure. In this study, we used a mouse model to test the hypothesis that aging increases the susceptibility to CS-induced pulmonary inflammation. We subjected 9-week-old and 69-week-old C57BL/6J mice to CS (whole-body exposure, 90 min/d), and evaluated neutrophil infiltration in the lungs, the levels of keratinocyte-derived chemokine (KC) and macrophage inflammatory protein (MIP)-2 in bronchoalveolar lavage fluid, and mRNA expression in bronchiolar epithelium retrieved by laser capture microdissection. The 69-week-old mice showed a greater number of neutrophils and higher levels of bronchiolar KC and MIP-2 expression than 9-week-old mice after 9 days of CS exposure. Furthermore, single CS exposure induced the rapid up-regulation of KC and MIP-2 in bronchiolar epithelium in both 9-week-old and 69-week-old mice, and the much higher levels in 69-week-old mice were associated with greater nuclear translocation of NF-kappaB. In contrast, no age-related differences were observed in the bronchiolar expression of NF-E2-related factor 2-regulated antioxidant and detoxification genes, heme oxygenase-1, reduced nicotinamide adenine dinucleotide phosphate quinone reductase 1, and glutamate-cysteine ligase, modifier unit, or antioxidant activity in bronchoalveolar lavage fluid, regardless of CS exposure. In summary, aging increases susceptibility to CS-induced inflammation in a mouse model, and robust mRNA up-regulation and nuclear translocation of NF-kappaB in bronchiolar epithelium may be involved.
  • [Flow-volume curve as an aid to diagnosis in double aortic arch masquerading as asthma in a young adult].
    Takayuki Yoshida, Satoshi Konno, Ayumu Takahashi, Yasuyuki Nasuhara, Tomoko Betsuyaku, Masaharu Nishimura
    Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society, 48, 3, 229, 34, 2010年03月, [査読有り], [国内誌]
    日本語, 研究論文(学術雑誌), We describe a young adult with double aortic arch who for several years had experienced stridor during exercise. He had been given a diagnosis of exercise-induced asthma, also known as hyperventilation syndrome. Antiasthmatic drugs, including inhaled corticosteroids and a short-acting bronchodilator, in addition to antidepressants, did not improve his symptoms. He had a history of allergic rhinitis and a familial history of asthma, but no signs of asthma as assessed by expectorated sputum and airway responsiveness (Dmin). However, flow-volume curves demonstrated a pattern consistent with upper airway constriction. Computed tomography confirmed severe tracheal narrowing caused by a double aortic arch. Compressive tracheal narrowing was also evaluated by fiber-optic tracheobronchoscopy. A treadmill exercise study induced respiratory distress with audible stridor that resolved itself without intervention. He underwent surgical division of the left aortic arch, which relieved the stridor during exercise. The flow-volume curve improved but constriction was still indicated even at 1.5 years after surgery. Double aortic arch should be considered in the differential diagnosis of drug-resistant stridor. This case re-emphasizes the value of flow-volume curves for diagnosing upper-airway obstruction.
  • Endobronchial actinomycosis associated with a foreign body--successful short-term treatment with antibiotics--.
    Maki K, Shinagawa N, Nasuhara Y, Oizumi S, Domen H, Haga H, Nishimura M
    Internal medicine (Tokyo, Japan), 49, 13, 1293, 1296, The Japanese Society of Internal Medicine, 2010年, [査読有り]
    英語, Primary endobronchial actinomycosis is a very rare condition. We report herein the case of a healthy 66-year-old woman who presented with right lower lobe endobronchial actinomycosis associated with aspiration of a foreign body, which was presumed to be a fish bone swallowed 28 months previously. The patient achieved complete clinical and radiological recovery after removal of the foreign body and 1-month antibiotic therapy of oral amoxycillin. Our experience in the management of this patient should help clinicians to realize the importance of bronchoscopic investigation and the management of this rare but treatable condition.
  • [Usefulness of fluorodeoxyglucose-positron emission tomography in a case of pleural sarcoidosis].
    Takeshi Hattori, Satoshi Konno, Takashi Inomata, Yasuyuki Nasuhara, Tomoko Betsuyaku, Masaharu Nishimura
    Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society, 47, 7, 658, 62, 2009年07月, [査読有り], [国内誌]
    日本語, 研究論文(学術雑誌), BACKGROUND: Pleural sarcoidosis is not a rare disease, and some patients with sarcoidosis experience chest pain, although the cause is often unknown. Various studies have indicated that fluorodeoxyglucose-positron emission tomography (FDG-PET) is useful for diagnosing and monitoring sarcoidosis. CASE: A 62-year-old man noted left-side dominant chest and back pain, although chest computed tomography (CT) revealed no abnormalities. Two months later, chest and back pain rapidly increased in severity and blurred vision appeared. In addition to uveitis, renal dysfunction was observed and chest CT on admission revealed enlargement of bilateral hilar/mediastinal lymph nodes and diffuse small nodular opacities and subpleural nodules, mainly in the segment of the left upper lobe (S1+2). FDG-PET revealed intense FDG uptake in bilateral peripheral lung parenchyma, spread widely along the subpleura and right inguinal lymph nodes with high uptake in the hilar and mediastinal lymph nodes. Sarcoidosis was diagnosed by transbronchial lung biopsy and renal biopsy. Oral corticosteroid treatment was performed due to persistent chest and back pain and rapid progression of renal dysfunction. Chest and back pain immediately disappeared and renal function improved. Follow-up FDG-PET performed 2 months after corticosteroid treatment revealed no areas of intense FDG uptake.
  • MS18-#4 喘息患者における血清シスタチンC値に関する検討(気管支喘息-診断と管理4,第59回日本アレルギー学会秋季学術大会)
    重村 雅彦, 今野 哲, 南須原 康行, 西村 正治
    アレルギー, 58, 8, 1254, 1254, 一般社団法人 日本アレルギー学会, 2009年
    日本語
  • [Efficacy of leukotriene receptor antagonists in asthma treatment and analysis of background factors evaluated by a questionnaire survey among physicians].
    Yoshinobu Fukui, Nobuyuki Hizawa, Daisuke Takahashi, Yukiko Maeda, Motoko Kobayashi, Yasuyuki Nasuhara, Masaharu Nishimura
    Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society, 46, 12, 972, 80, 2008年12月, [査読有り], [国内誌]
    日本語, 研究論文(学術雑誌), The efficacy of leukotriene receptor antagonists (LTRAs) in the treatment of asthma and the involvement of various patient background factors were investigated. A questionnaire was used to survey the physicians of 1,600 asthma patients regarding the use of LTRAs, whether treatment was being continued or had been discontinued, and reasons for continuation or discontinuation. The results showed that 797 patients had used an LTRA, with 468 having used pranlukast (P), 294 having used montelukast (M) and 25 having used zafirlukast. For the remaining 10 patients, either the drug name was unknown or multiple LTRAs had been used. The P Group was slightly younger in age (median: P, 55 years, M, 57 years) and had a higher frequency of mild, intermittent disease (P: 20.3%; M:11.2%). The P Group also had a higher percentage of patients who continued taking an LTRA because the drug was "clearly effective" (P: 34.6%; M: 17.3%), and a lower percentage of patients who discontinued the drug because the drug was "ineffective" (P: 2.6%; M:19.0%). Logistic regression analysis showed the following as independent factors contributing to efficacy of the LTRA in the treatment of the asthma (R2 = 0.19): P as the drug used (p < 0.01); allergic rhinitis not present as a complication (p < 0.01); and mild severity of asthma (p = 0.02). Further, the present findings indicate that LTRAs are highly effective for patients who have mild asthma without complication by allergic rhinitis. Further investigation is necessary to determine differences in efficacy among different LTRAs.
  • the Hokkaido COPD Cohort Study Group Functional SNPs of the CCL5 gene and non-emphysematous phenotype in patients with COPD.               
    Hizawa, N, Makita H, Nasuhara Y, Hasegawa M, Nagai K, Ito Y, Betsuyaku T, Konno S, Nishimura M
    Eur Respir J., 32, 2, 372-378, 2008年01月, [査読有り]
    英語, 研究論文(学術雑誌)
  • beta(2)-Adrenergic receptor genetic Polymorphisms and short-term bronchodilator responses in patients with COPD
    Hizawa, Nobuyuki, Makita, Hironi, Nasuhara, Yasuyuki, Betsuyaku, Tomoko, Roh, Yoko, Nagai, Katsura, Hasegawa, Masant, Nishimura, Masaham
    CHEST, 132, 5, 1485, 1492, AMER COLL CHEST PHYSICIANS, 2007年11月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Lipopolysaccaride-induced neutrophilic inflammation in the lungs differs with age
    Yoko Ito, Tomoko Betsuyaku, Yasuyuki Nasuhara, Masaharu Nishimura
    EXPERIMENTAL LUNG RESEARCH, 33, 7, 375, 384, TAYLOR & FRANCIS INC, 2007年, [査読有り]
    英語, 研究論文(学術雑誌), In aged humans and animals, lung injuries are generally more serious and prolonged. From a kinetic perspective, the authors thus assessed whether lung expression of proinflammatory cytokines were altered with age following intratracheal lipopolysaccharide (LPS) challenge in mice. Tumor necrosis factor-alpha, interleukin-1 beta, macrophage inflammatory protein-1 alpha, macrophage inflammatory protein-2, and keratinocyte-derived chemokine were significantly higher in 65-week-old mice along with sustained neutrophilia when compared to 11-week-old mice at 72 hours, but not at earlier time points. The authors concluded that the degree of LPS-induced neutrohilic inflammation and the expression of these cytokines differ with age at later phases of acute lung injury.
  • [Cibenzoline succinate induced pneumonitis].
    Hasegawa M, Nasuhara Y, Maki N, Miura T, Betsuyaku T, Hizawa N, Nishimura M, Onozuka H, Tsutsui H
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 95, 7, 1362, 1364, 7, 2006年07月, [査読有り]
    日本語, 症例は70歳男性. 発作性心房細動に対し, コハク酸シベンゾリン (シベノール®) の服用を開始したところ, 15日目ごろより労作時呼吸困難を自覚し, 25日目に胸部異常陰影を指摘された. 抗生剤投与にて改善がみられないため, 我々はコハク酸シベンゾリンによる薬剤性肺炎も疑い, 同剤を中止した上でステロイド治療を施行した. 肺炎の改善を認めたが発作性心房細動が再発したため, 慎重な観察の下同剤を再開したところ肺炎の再増悪を認めた. 以上よりコハク酸シベンゾリンによる薬剤性肺炎と診断した.
  • Long term smoking with age builds up excessive oxidative stress in bronchoalveolar lavage fluid
    K. Nagai, T. Betsuyaku, T. Kondo, Y. Nasuhara, M. Nishimura
    Thorax, 61, 6, 496, 502, 2006年06月
    英語, 研究論文(学術雑誌), Background: Epithelial lining fluid plays a critical role in protecting the lung from oxidative stress, in which the oxidised status may change by ageing, smoking history, and pulmonary emphysema. Methods: Bronchoalveolar lavage (BAL) was performed on 109 young and older subjects with various smoking histories. The protein carbonyls, total and oxidised glutathione were examined in BAL fluid. Results: By Western blot analysis, the major carbonylated protein in the BAL fluid was sized at 68 kDa, corresponding to albumin. The amount of carbonylated albumin per mg total albumin in BAL fluid was four times higher in older current smokers and three times higher in older former smokers than in age matched non-smokers (p<
    0.0001, p = 0.0003, respectively), but not in young smokers. Total glutathione in BAL fluid was significantly increased both in young (p = 0.006) and older current smokers (p = 0.0003) compared with age matched non-smokers. In contrast, the ratio of oxidised to total glutathione was significantly raised (72%) only in older current smokers compared with the other groups. There was no significant difference in these parameters between older smokers with and without mild emphysema. Conclusions: Oxidised glutathione associated with excessive protein carbonylation accumulates in the lung of older smokers with long term smoking histories even in the absence of lung diseases, but they are not significantly enhanced in smokers with mild emphysema.
  • Decrease of vascular endothelial growth factor in macrophages from long-term smokers
    K Nagal, T Betsuyaku, Y Ito, Y Nasuhara, M Nishimura
    EUROPEAN RESPIRATORY JOURNAL, 25, 4, 626, 633, EUROPEAN RESPIRATORY SOC JOURNALS LTD, 2005年04月, [査読有り]
    英語, 研究論文(学術雑誌), Vascular endothelial growth factor (VEGF), a survival factor for endothelial cells and a promoter of angiogenesis, is reportedly expressed in alveolar macrophages (AMs).
    To investigate whether long-term smoking with age affects VEGF expression in AMs, bronchoalveolar lavage (BAL) was performed on 18 young and 23 older volunteers with various smoking histories. The expressions of VEGF and its functional receptor, fms-like tyrosine kinase (Fit)-1, were quantified in AMs by real-time RT-PCR and, further, the level of VEGF in BAL fluid was determined by ELISA.
    VEGF mRNA in AMs demonstrated a 1.8-fold reduction in current smokers compared with nonsmokers in older subjects and, furthermore, a 1.5-fold downregulation in those with emphysema, although there was no difference between current smokers and nonsmokers, among the young subjects. The downregulation in total VEGF mRNA was supported by the substantial reduction of VEGF121 and VEGF165 isoforms. However, in contrast, Flt-1 mill did not differ within the older groups, whereas it was upregulated in young current smokers compared with age-matched nonsmokers. VEGF in BAL fluid is significantly decreased in current smokers compared with nonsmokers, regardless of their age.
    In conclusion, these data imply that the biological availability of vascular endothelial growth factor in alveolar macrophages is impaired in older current smokers with long-term smoking histories.
  • 114 喘息におけるロイコトリエン受容体拮抗薬の有効性とその背景の検討 : アンケートの結果
    福居 嘉信, 檜澤 伸之, 高橋 大輔, 前田 由起子, 小林 基子, 南須原 康行, 西村 正治
    アレルギー, 54, 3, 349, 349, 一般社団法人 日本アレルギー学会, 2005年
    日本語
  • 4 COPDの病態における細気管支上皮の抗酸化機構, 炎症関連遺伝子発現(13 慢性気道炎症における気道上皮細胞の役割, 第55回日本アレルギー学会秋季学術大会)
    別役 智子, 福家 聡, 南須原 康行, 西村 正治
    アレルギー, 54, 8, 920, 920, 一般社団法人 日本アレルギー学会, 2005年
    日本語
  • Effects of ageing and smoking on SP-A and SP-D levels in bronchoalveolar lavage fluid
    Tomoko Betsuyaku, Y. Kuroki, K. Nagai, Y. Nasuhara, M. Nishimura
    European Respiratory Journal, 24, 6, 964, 970, 2004年12月
    英語, 研究論文(学術雑誌), Surfactant protein (SP)-A and SP-D are collagen-like glycoproteins that are synthesized in the distal pulmonary epithelium. This study examined the effects of ageing and long-term smoking on SP-A and SP-D in the lungs. The possible links to the development of pulmonary emphysema were also investigated. Sequential lavage was performed in young and middle-aged or elderly nonsmokers and asymptomatic current smokers with various smoking histories. Middle-aged or elderly smokers were further categorised according to the presence of emphysema by high-resolution computed tomography. Levels of SP-A and SP-D in bronchial lavage (BL) fluid and in bronchoalveolar lavage (BAL) fluid were quantified by ELISA. Significant decreases in SP-A were seen with age in nonsmokers in BL fluid, but not in BAL fluid. Middle-aged or elderly smokers with emphysema had lower levels of SP-A in both BL and BAL fluids when compared with young subjects, and in BL fluid when compared with middle-aged or elderly smokers without emphysema. SP-D did not change with age alone, however, it was decreased in middle-aged or elderly smokers when compared with similarly aged nonsmokers. In conclusion, surfactant protein-A may decrease with age alone or due to the cumulative effects of long-term smoking and development of emphysema, while surfactant protein-D decreases due to long-term smoking. © ERS Journals Ltd 2004.
  • Chemokines in bronchiolar epithelium in the development of chronic obstructive pulmonary disease
    S Fuke, T Betsuyaku, Y Nasuhara, T Morikawa, H Katoh, M Nishimura
    AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 31, 4, 405, 412, AMER THORACIC SOC, 2004年10月, [査読有り]
    英語, 研究論文(学術雑誌), The inflammatory chemokines interleukin-8, macrophage inflammatory protein-1alpha, and monocyte chemoattractant protein-1, are reportedly involved in the pathogenesis of chronic obstructive pulmonary disease (COPD). Although bronchiolar epithelial cells and macrophages are known to be the cellular sources, the relative contribution of each cell type remains to be elucidated. In the present study, we first quantified cytokine mRNA in human bronchiolar epithelial cells and macrophages obtained using laser-capture microdissection and explored the relationship with early-stage COPD. Only in bronchiolar epithelial cells were interleukin-8, macrophage inflammatory protein-lot, and monocyte chemoattractant protein-1 mRNA levels higher in smokers with airflow limitation and/or emphysema than those in never-smokers or smokers without either airflow limitation or emphysema. No difference was observed in macrophages. Complementary DNA (cDNA) array further revealed the overexpression of CC chemokine receptor 2 in bronchiolar epithelial cells from smokers with airflow limitation and/or emphysema. This study supports the role of bronchiolar epithelium as the source of increased inflammatory chemokine levels in the early development of COPD and also demonstrates the potential use of laser-capture microdissection, combined with reverse transcriptase-polymerase chain reaction and cDNA microarrays, to investigate functional profiles of individual structural and inflammatory cells in human lungs.
  • Effect of low-dose theophylline on airway inflammation in COPD
    Motoko Kobayashi, Yasuyuki Nasuhara, Tomoko Betsuyaku, Eiji Shibuya, Yoshinori Tanino, Mishie Tanino, Kei Takamura, Katsura Nagai, Takeshi Hosokawa, Masaharu Nishimura
    Respirology, 9, 2, 249, 254, 2004年06月
    英語, 研究論文(学術雑誌), Objective: Recent studies have shown that theophylline may exert anti-inflammatory effects on neutrophils. We undertook to assess the effect of theophylline on airway inflammation in COPD. Methodology: We performed a 4-week randomized double-blind, placebo-controlled study in 11 theophylline-naive patients with mild to moderate COPD. After a 1-week run-in period, six subjects were administered 400 mg/day theophylline (Theodur
    Nikken Chemicals Co. Ltd, Tokyo, Japan) for 4 weeks, while five subjects were administered a placebo. Induced sputum was obtained before and after the run-in period and then after 2 and 4 weeks of treatment. Cell differential count and levels of interleukin-8, matrix metalloproteinase-9, neutrophil elastase (NE), myeloperoxidase (MPO), α1-antitrypsin (αs1-AT), leukotriene B 4 and tissue inhibitor of metalloproteinases-1 (TIMP-1) were assessed. Results: No variable was significantly different during the run-in period or with placebo treatment. In contrast, theophylline treatment significantly decreased NE and MPO levels at 4 weeks, although the cell differential count did not change appreciably as a result of treatment. Conclusion: These results suggest that 4 weeks of theophylline treatment attenuates neutrophil-associated inflammation in the airways of mild to moderate COPD patients. However, the clinical benefits remain to be determined.
  • Retinoic acid inhibits interleukin-4-induced eotaxin production in a human bronchial epithelial cell line
    K Takamura, Y Nasuhara, M Kobayashi, T Betsuyaku, Y Tanino, Kinoshita, I, E Yamaguchi, S Matsukura, RP Schleimer, M Nishimura
    AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 286, 4, L777, L785, AMER PHYSIOLOGICAL SOC, 2004年04月, [査読有り]
    英語, 研究論文(学術雑誌), Retinoic acid (RA) is known to accelerate wound healing and induce cell differentiation. All-trans RA (ATRA) exerts its effect by binding retinoic acid receptors, which are members of the nuclear receptor family. We investigated whether RA can alter expression of eotaxin, a potent eosinophil chemoattractant that is regulated by the transcription factors signal transducer and activator of transcription 6 (STAT6) and NF-kappaB. We examined the effects of RA on eotaxin expression in a human bronchial epithelial cell line BEAS-2B. ATRA and its stereodimer 9-cis retinoic acid (9-cis RA) inhibited IL-4-induced release of eotaxin at 10(-6) M by 78.0 and 52.0%, respectively (P < 0.05). ATRA and 9-cis RA also significantly inhibited IL-4-induced eotaxin mRNA expression at 10(-6) M by 52.3 and 53.5%, respectively (P < 0.05). In contrast, neither ATRA nor 9-cis RA had any effects on TNF-alpha-induced eotaxin production. In transfection studies using eotaxin promoter luciferase plasmids, the inhibitory effect of ATRA on IL-4-induced eotaxin production was confirmed at the transcriptional level. Interestingly, ATRA had no effects on IL-4-induced tyrosine phosphorylation, nuclear translocation, or DNA binding activity of STAT6. Activating protein-1 was not involved in ATRA-mediated transrepression of eotaxin with IL-4 stimulation. The mechanism of the inhibitory effect of ATRA on IL-4-induced eotaxin production in human bronchial epithelial cells has not been elucidated but does not appear to be due to an effect on STAT6 activation. These findings raise the possibility that RA may reduce eosinophilic airway inflammation, one of the prominent pathological features of allergic diseases such as bronchial asthma.
  • [A case of paclitaxel-induced pneumonitis].
    Taniguchi N, Shinagawa N, Kinoshita I, Nasuhara Y, Yamazaki K, Yamaguchi E, Akita H, Nishimura M
    Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society, 42, 158, 163, 2, 2004年02月, [査読有り]
  • 38 ムスカリン受容体M1遺伝子多型と喘息発症の関連
    前田 由起子, 檜澤 伸之, 地主 英世, 小林 基子, 高橋 大輔, 福居 嘉信, 別役 智子, 南須原 康行, 西村 正治
    アレルギー, 53, 8, 890, 890, 一般社団法人 日本アレルギー学会, 2004年
    日本語
  • Studies on airway hyperresponsiveness by the astograph® method in asthmatics and young adult non-asthmatic asymptomatics
    Yoshinobu Fukui, Etsuro Yamaguchi, Nobuyuki Hizawa, Yukiko Maeda, Daisuke Takahashi, Satoshi Konno, Motoko Kobayashi, Takeshi Hosokawa, Eisei Jinushi, Kei Takamura, Yasuyuki Nasuhara, Masaharu Nishimura
    Japanese Journal of Allergology, 53, 6, 565, 574, 2004年, [査読有り]
    日本語, 研究論文(学術雑誌), We investigated airway hyperresponsiveness (AHR) by the continuous inhalation method using an Astograph® in 105 asthmatics and 141 non-asthmatic asymptomatics. The range of Dmin (1 U = one minute inhalation of 1 mg/ml of methacholine) of asthmatics was 0.001 to 28.70 U, and that of adjusted Dmin of non-asthmatic asymptomatics was 0.28 to 190 U
    thus, an apparent overlap was recognized in the distributions of Dmin. Ninety-five percent of asthmatics had a Dmin lower than 7 U, and 95% of non-asthmatic asymptomatics had a Dmin higher than 0.9 U. Presuming that almost all asthmatics had AHR, it was inferred that nearly half of non-asthmatic asymptomatics had AHR, too. Comparison with previous reports suggests that AHR in healthy people may be increasing generally. When Dmin is determined to be >
    7 U by the Astograph® method, it is likely that the patient does not have asthma. When a patient has a Dmin <
    0.9 U, it is highly probable that the patient has asthma.
  • Extracellular matrix metalloproteinase inducer is increased in smokers' bronchoalveolar lavage fluid
    T Betsuyaku, M Tanino, K Nagai, Y Nasuhara, M Nishimura, RM Senior
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 168, 2, 222, 227, AMER THORACIC SOC, 2003年07月, [査読有り]
    英語, 研究論文(学術雑誌), Extracellular matrix metalloproteinase inducer (EMMPRIN), also called basigin, is present in the lung during development, but its expression in normal adult lung is minimal. Increases of EMMPRIN have been found in various forms of experimental lung injury. To determine whether EMMPRIN might be involved in alveolar injury/ repair associated with smoking, we developed an ELISA for EMMPRIN and applied it to bronchoalveolar lavage fluids from never-smokers (n = 7), former smokers (n = 16), and current smokers (n = 58). The smoker groups included subjects with emphysema, as determined by high-resolution chest computed tomography. EMMPRIN levels were significantly elevated in current and former smokers (315 +/- 20 and 175 +/- 15 pg/ml SEM, respectively, compared with 31 +/- 7 pg/ml in never-smokers), but the EMMPRIN levels of smokers with emphysema were not different from smokers without emphysema. Immunohistochemistry of smokers' lung tissue showed EMMPRIN in bronchiolar epithelium and alveolar macrophages, but EMMPRIN mRNA in alveolar macrophages was not different between current and never-smokers. Matrix metalloproteinase-1 was also detectable in the bronchoalveolar lavage fluid from some smokers but not in never-smokers. These findings indicate that smoking is associated with increased intrapulmonary EMMPRIN. Whether EMMPRIN is involved in smoking-induced lung pathology remains to be determined.
  • 84 アストグラフ法による気道過敏性の指標における基準範囲の検討
    福居 嘉信, 今野 哲, 小林 基子, 地主 英世, 高村 圭, 南須原 康行, 檜澤 伸之, 山口 悦郎, 西村 正治
    アレルギー, 51, 9, 927, 927, 一般社団法人 日本アレルギー学会, 2002年
    日本語
  • 4 喘息とβ-受容体、ムスカリン受容体の遺伝子多型(2 アレルギー性疾患と遺伝)
    檜澤 伸之, 山口 悦郎, 地主 英世, 今野 哲, 南須原 康行, 棟方 充, 川上 義和
    アレルギー, 49, 9, 801, 801, 一般社団法人 日本アレルギー学会, 2000年
    日本語
  • Inhibition of ozone-induced lung neutrophilia and nuclear factor-kappa B binding activity by vitamin A in rat
    T Hisada, IM Adcock, Y Nasuhara, M Salmon, TJ Huang, PJ Barnes, KF Chung
    EUROPEAN JOURNAL OF PHARMACOLOGY, 377, 1, 63, 68, ELSEVIER SCIENCE BV, 1999年07月
    英語, 研究論文(学術雑誌), Vitamin A binds to retinoic acid receptors, which in turn may interact with other transcription factors. We determined its effect (2500 and 5000 IU/kg) on nuclear factor-kappa B binding activity in the lung, airway inflammation and bronchial hyperresponsiveness in rats exposed to ozone. Ozone (3 ppm, 3 h) caused neutrophil influx into bronchoalveolar lavage fluid (16.2 +/- 0.8 x 10(5) cells/ml, p < 0.01) and bronchial hyperresponsiveness (-logPC(200)ACh = 2.54 +/- 0.19, p < 0.05, compared to control animals, respectively). Vitamin A inhibited this neutrophilia dose-dependently together with the increased DNA-binding activity of nuclear factor-kappa B in lung extracts. Vitamin A did not affect bronchial hyperresponsiveness at both doses. Vitamin A inhibits ozone-induced neutrophilic inflammation through a reduction in nuclear factor-kappa B DNA binding activity. (C) 1999 Elsevier Science B.V. All rights reserved.
  • Role of cysteinyl-leukotrienes in eotaxin-induced bronchial hyperresponsiveness and eosinophil migration in IL-5 transgenic mice
    T Hisada, M Salmon, Y Nasuhara, KF Chung
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 159, 3, A404, A404, AMER LUNG ASSOC, 1999年03月
    英語
  • エトポシド,ステロイド併用療法が著効を示した菌状息肉症肺病変の1例
    南須原 康行, 小林 秀一, 棟方 充, 川上 義和, 藤田 美悧
    日本胸部疾患学会雑誌, 33, 9, 1013, 1018, The Japanese Respiratory Society, 1995年
    日本語, 症例は75歳の男性. 菌状息肉症の皮膚病変の治療経過中に咳嗽, 血痰が出現するようになり当科を受診. 胸部X線写真にて広範囲に結節影, 粒状・網状影が認められ, 経気管支肺生検にて菌状息肉症の肺病変と診断した. 当初, 悪性リンパ腫に準じてVEPA療法を行ったが皮膚病変が増悪し, 更に細菌性肺炎, 十二指腸潰瘍を併発した. 全身状態回復後, 少量エトポシド, プレドニゾロンの併用療法を施行したところ, 皮膚・肺病変ともに著明な改善を示し, その効果はエトポシド少量内服療法に移行した後も長期間継続した. 一般に肺病変を伴った菌状息肉症の予後は不良とされているが, 本症例では, 少量エトポシド, ステロイド併用療法にて長時間コントロール可能であり, 肺などの内臓病変をきたした進行期の菌状息肉症に対して, 考慮すべき治療法の一つと考えられる.

その他活動・業績

  • 7対1看護導入がインシデント報告件数に与えた影響について 新人看護職数の増加に着目して
    南須原 康行, 佐久嶋 研, 奥原 芳子, 渋谷 かをり, 伊藤 陽一, 石川 誠, 宝金 清博, 日本医療マネジメント学会雑誌, 14, 1, 25, 30, 2013年05月
    北海道大学病院における2003年度から2009年度までの7年間にわたるインシデントレポートの中から、看護職によって報告されたものを抽出し、報告者の経験年数、レポート件数、場面などについて分析を行った。7年間で看護職から報告されたインシデントレポート総数は12,798件であった。7対1看護の導入により2007年度に145名の看護職の増員があり、総看護職の増員が22.0%であったのに対し、インシデントレポート件数は33.0%の増加であった。2007年度は総看護職数における1年目看護職数の割合が高く、1年目看護職による報告件数の占める割合が他の年度と比較して高かった。一方、1年目看護職1人あたりの平均年間報告件数の経年変化をみると、2007年度はそれ以前に比べて増加していなかった。看護職の増員は、看護職1人あたりのインシデントレポート件数の減少には繋がらなかった。看護職1年目ではインシデント全体に占める処方・与薬の割合が、2・3年目、4年目以上と比較して有意に大きかった。その内訳では、末梢静脈点滴なかでも投与速度に関するものの割合が、1年目および2・3年目は4年目以上に比べて有意に大きかった。看護職の新人教育においては、新人が関与する可能性の高いインシデントに重点をおいた教育が必要であろう。(著者抄録), (NPO)日本医療マネジメント学会, 日本語
  • 肺胞蛋白症のGM‐CSF吸入治療の予後と肺活量
    田澤立之, 新井徹, 笠原靖紀, 放生雅章, 大河内眞也, 江田良輔, 横場正典, 土橋佳子, 中山秀章, 石井晴之, 森本浩之輔, 南須原康行, 高田俊範, 海老名雅仁, 山口悦郎, 井上義一, 中田光, 日本呼吸器学会誌, 2, 増刊, 223, 223, 2013年03月10日
    (一社)日本呼吸器学会, 日本語
  • 医療安全管理部と診療録管理室協働による診療録監査の取り組み
    初山 貴, 勝谷 剛, 佐々木 綾香, 横山 瑠奈, 齊藤 恵里佳, 渋谷 かをり, 奥原 芳子, 石川 誠, 南須原 康行, 寶金 清博, 診療情報管理 : 日本診療情報管理学会誌 = Health information management, 24, 3, 68, 71, 2012年12月25日
    日本診療情報管理学会, 日本語
  • 転倒・転落防止及び対応に関する看護師の意識調査
    南須原 康行, 佐久嶋 研, 奥原 芳子, 渋谷 かをり, 石川 誠, 伊藤 陽一, 宝金 清博, 医療の質・安全学会誌, 7, Suppl., 205, 205, 2012年10月
    (一社)医療の質・安全学会, 日本語
  • Beta2-adrenergic receptor polymorphisms as a determinant of preferential bronchodilator responses to beta 2-agonist and anticholinergic agents in Japanese patients with chronic obstructive pulmonary disease
    Satoshi Konno, Hironi Makita, Masaru Hasegawa, Yasuyuki Nasuhara, Katsura Nagai, Tomoko Betsuyaku, Nobuyuki Hizawa, Masaharu Nishimura, PHARMACOGENETICS AND GENOMICS, 21, 11, 687, 693, 2011年11月, [査読有り]
    Background Previous studies have shown that polymorphisms in the beta 2-adrenergic receptor gene (ADRB2) may influence bronchodilator response (BDR) to both beta 2-agonists and anticholinergics, possibly by intracellular cross-talk, but in opposite ways, in the Japanese population. We hypothesized that the preferential response to either class of bronchodilators might be determined by ADRB2 polymorphisms in patients with chronic obstructive pulmonary disease (COPD).
    Objective To examine the association of ADRB2 polymorphisms and preferential BDR to beta 2-agonists and anticholinergics in patients with COPD.
    Design and participants The participants had been enrolled in the Hokkaido COPD cohort study. BDR to either class of bronchodilators (salbutamol or oxytropium, 0.4 mg) was measured every 6 months for 2 years. Considering the variation of BDR within and between days, mean values of postbronchodilator increases in forced expiratory volume in 1 s (Delta FEV1) for the two agents measured at two different visits were initially used for the primary analysis (N = 189). To confirm the results of the primary analysis, Delta FEV1 measured at a single visit was also used for secondary analyses.
    Results Although a significant correlation between BDRs to salbutamol and to oxytropium was observed (P < 0.001, r = 0.36), there were individuals who responded preferentially to one of the two agents. When the participants were classified into two groups based on the bronchodilator causing the better response (salbutamol-dominant group and oxytropium-dominant group), Arg allele was significantly more common in the oxytropium-dominant group than in the salbutamol-dominant group (0.001 < P < 0.05).
    Conclusion ADRB2 polymorphism may be a determinant of preferential BDR to either beta 2-agonists or anticholinergics in patients with COPD. Pharmacogenetics and Genomics 21:687-693 (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins., LIPPINCOTT WILLIAMS & WILKINS, 英語
  • 当院における成人用転倒・転落アセスメントシートの妥当性についての検討               
    南須原 康行, 佐久嶋 研, 伊藤 陽一, 奥原 芳子, 渋谷 かをり, 石川 誠, 寶金 清博, 医療の質・安全学会誌, 6, Suppl., 176, 176, 2011年10月
    (一社)医療の質・安全学会, 日本語
  • Comparison of airway remodelling assessed by computed tomography in asthma and COPD
    Kaoruko Shimizu, Masaru Hasegawa, Hironi Makita, Yasuyuki Nasuhara, Satoshi Konno, Masaharu Nishimura, RESPIRATORY MEDICINE, 105, 9, 1275, 1283, 2011年09月, [査読有り]
    Background: Few studies have directly compared airway remodelling assessed by computed tomography (CT) between asthma and chronic obstructive pulmonary disease (COPD). The present study was conducted to determine whether there are any differences between the two diseases with similar levels of airflow limitation under clinically stable conditions.
    Methods: Subjects included older male asthmatic patients (n = 19) showing FEV(1)/FVC <70% with smoking history less than 5-pack/year. Age- and sex-matched COPD patients (n = 28) who demonstrated similar airflow limitation as asthmatic patients and age-matched healthy non-smokers (n = 13) were recruited. Using proprietary software, eight airways were selected in the right lung, and wall area percent (WA%) and airway luminal area (Ai) were measured at the mid-portion of the 3rd to 6th generation of each airway. For comparison, the average of eight measurements per generation was recorded.
    Results: FEV(1)% predicted and FEV(1)/FVC was similar between asthma and COPD (82.3 +/- 3.3% vs. 77.6 +/- 1.8% and 57.7 +/- 1.6% vs. 57.9 +/- 1.4%). At any generation, WA% was larger and Ai was smaller in asthma, both followed by COPD and then controls. Significant differences were observed between asthma and controls in WA% of the 3rd to 5th generation and Ai of any generation, while no differences were seen between COPD and controls. There were significant differences in Ai of any generation between asthma and COPD., W B SAUNDERS CO LTD, 英語
  • Two Atypical Cases Of Hard Metal Lung Disease
    T. Hosokawa, H. Terui, T. Ogi, C. Moriyama, A. Isada, K. Nagai, S. Konno, Y. Nasuhara, M. Nishimura, K. Kubota, Y. Matsuno, A. Morioka, I. Nakano, K. Kimura, K. Okamoto, M. Uo, AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 183, 2011年, [査読有り]
    AMER THORACIC SOC, 英語, 研究発表ペーパー・要旨(国際会議)
  • 結節性硬化症病変を伴わないmultifocal micronodular pneumocyte hyperplasia の1例               
    日本呼吸器学会雑誌, 49, 5, 355, 359, 2011年
    速報,短報,研究ノート等(学術雑誌)
  • A Case of Follicular Bronchiolitis Associated with Asthma, Eosinophilia, and Increased Immunoglobulin E
    Kaoruko Shimizu, Satoshi Konno, Yasuyuki Nasuhara, Mishie Tanino, Yoshihiro Matsuno, Masaharu Nishimura, JOURNAL OF ASTHMA, 47, 10, 1161, 1164, 2010年12月, [査読有り]
    A 49-year-old woman, who had been diagnosed with asthma, showed a bilateral diffuse pattern of small centrilobular nodules on CT. Laboratory data revealed peripheral eosinophilia and a marked increase in total serum IgE levels. The nodules detected on CT were initially considered to be associated with bronchiolar infiltration of eosinophils. Pathological findings from thoracoscopy revealed infiltration of eosinophils into the airway lumen and walls, goblet cell hyperplasia, and thickening of the basement membrane in large bronchi, consistent with asthma. However, hyperplastic lymphoid follicles with reactive germinal centers were observed along the bronchioles. The follicles had no evidence of monoclonality suggested by immunohistological analysis, and no remarkable infiltrates of eosinophils, suggesting follicular bronchiolitis (FB). After treatment with prednisolone, the small diffuse nodules improved markedly, and peripheral eosinophilia and total serum IgE levels also decreased. To the best of our knowledge, this is the first documented case report of FB associated with asthma, eosinophilia, and elevated IgE with a definite pathophysiological diagnosis., INFORMA HEALTHCARE, 英語, 速報,短報,研究ノート等(学術雑誌)
  • Airflow limitation and airway dimensions assessed per bronchial generation in older asthmatics
    Kaoruko Shimizu, Masaru Hasegawa, Hironi Makita, Yasuyuki Nasuhara, Satoshi Konno, Masaharu Nishimura, RESPIRATORY MEDICINE, 104, 12, 1809, 1816, 2010年12月, [査読有り]
    Background Computed tomography (CT) has been used for non invasive quantitative assessment of airway dimensions, potentially showing airway remodeling, in asthma However, most studies have examined either only one airway or only airways in anatomically unidentified cross sections Using software capable of precisely identifying the generation of airways and measuring airway dimensions perpendicular to the long axis of airways, we examined, in older patients with stable asthma, how inter subject variation in airway dimensions correlated among the 3rd to 6th generation of airways, and then examined relationships between airway dimensions of each generation and indices of airflow limitation
    Methods Subjects aged >= 55 years old comprised 59 asthmatic patients who underwent CT and pulmonary function tests on the same day We measured airway wall area (WA%) and innerluminal area (Ai) from the 3rd to the 6th generation of eight bronchi in the right lung
    Results Excellent correlations were identified for both WA% and Ai among the generations (r = 0 744-0 930 for WA%) when we took the average of all measured bronchi per generation as a personal representative value Significant correlations of airflow limitation indices with both WA% and Ai/BSA were found at each of the 3rd to 6th generations with similar correlation coefficients (WA% for FEV(1) %predicted, r = -0 410 to -0 556)
    Conclusions In older patients with stable asthma, airway wall thickening and narrowing might occur in a parallel manner through 3rd to 6th generation airways Airway dimensions at these areas of airways may thus have significant and similar correlations with indices of airflow limitation (C) 2010 Elsevier Ltd All rights reserved, W B SAUNDERS CO LTD, 英語, 速報,短報,研究ノート等(学術雑誌)
  • O14-3 肺CT3次元気道解析を用いた気管支喘息とCOPDにおける気道病変の比較(O14 喘息画像解析,口演,第60回日本アレルギー学会秋季学術大会)
    清水 薫子, 長谷川 大, 牧田 比呂仁, 南須原 康行, 今野 哲, 西村 正治, アレルギー, 59, 9, 1384, 1384, 2010年10月30日
    一般社団法人日本アレルギー学会, 日本語
  • 喘息として加療されフローボリューム子九千が発見の契機となった成人重複大動脈弓の1例               
    日本呼吸器学会雑誌, 48, 3, 229, 234, 2010年
    速報,短報,研究ノート等(学術雑誌)
  • 高度の肺野病変を呈した血管内大細胞型B細胞リンパ腫
    血液臨床, 51, 5, 353, 356, 2010年
    速報,短報,研究ノート等(学術雑誌)
  • MPO-ANCA陽性であったが糸球体腎炎や血管炎は確認されず、間質性肺炎に感染症を合併して死亡した症例
    石津 明洋, 岩崎 沙理, 外丸 詩野, 武田 広子, 大塚 紀幸, 富居 一範, 笠原 正典, 清水 健一, 南須原 康行, 西村 正治, 北海道医学雑誌, 84, 5, 403, 403, 2009年09月
    北海道医学会, 日本語
  • Comparison of the Pharmacodynamics of Biapenem in Bronchial Epithelial Lining Fluid in Healthy Volunteers Given Half-Hour and Three-Hour Intravenous Infusions
    Eiki Kikuchi, Junko Kikuchi, Yasuyuki Nasuhara, Satoshi Oizumi, Akitoshi Ishizaka, Masaharu Nishimura, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 53, 7, 2799, 2803, 2009年07月, [査読有り]
    The time above the MIC (T>MIC) is the pharmacokinetic/pharmacodynamic (PK/PD) parameter that correlates with the therapeutic efficacy of beta-lactam antibiotics. A prolonged infusion can provide plasma drug concentrations that remain above the MIC for a long period. The objective of this study was to compare the PK/PD parameters in bronchial epithelial lining fluid (ELF) of biapenem given as 0.5-h and 3-h infusions by using bronchoscopic microsampling (BMS). Six healthy adult volunteers received 0.5-h and 3-h infusions of 0.3 g of biapenem with a washout interval. BMS was performed repeatedly from 0.5 to 24 h after biapenem administration in order to determine the pharmacokinetics in bronchial ELF. The subjects received intravenous biapenem with the same regimens again and then underwent bronchoalveolar lavage (BAL) at the end of infusion in order to determine the concentration of the drug in alveolar ELF. The percentages (means +/- standard deviations) of T>MIC in bronchial ELF at MICs from 0.25 to 4 mu g/ml ranged from zero to 34.6% +/- 5.2% after the 0.5-h infusion and from 5.1% +/- 5.6% to 52.2% +/- 17.0% after the 3-h infusion. The percentage of T>MIC in bronchial ELF after the 3-h infusion tended to be higher than that after the 0.5-h infusion. The concentrations of the drug in alveolar ELF after 0.5-h and 3-h infusions were 3.5 +/- 1.2 mu g/ml and 1.3 +/- 0.3 mu g/ml, respectively. The present results support the use of prolonged infusions of beta-lactam antibiotics and may provide critical information for successful treatment of lower respiratory tract infections based on PK/PD parameters in bronchial ELF., AMER SOC MICROBIOLOGY, 英語
  • Relationship between improved airflow limitation and changes in airway calibre induced by inhaled anticholinergic agents in COPD
    M. Hasegawa, H. Makita, Y. Nasuhara, N. Odajima, K. Nagai, Y. Ito, T. Betsuyaku, M. Nishimura, THORAX, 64, 4, 332, 338, 2009年04月, [査読有り]
    Background: Although airflow limitation improved by inhaled anticholinergic drugs varies among individuals with chronic obstructive pulmonary disease (COPD), the relationship between actual bronchodilation and improved pulmonary function and where in the lung such bronchodilation occurs remains unknown. A study was undertaken to determine the relationship between improved pulmonary function and changes in airway calibre at various sites in the airways in response to inhaled anticholinergic agents in patients with COPD using three-dimensional computed tomography (CT).
    Methods: CT scans were performed at deep inspiration and detailed pulmonary function tests before and 1 week after daily inhalations of tiotropium bromide in 15 patients with clinically stable COPD. The airway luminal area was examined at the third (segmental) to the sixth generations of eight bronchi in the right lung.
    Results: Bronchodilation was demonstrated by an overall average increase of 39% in the inner luminal area, and the mean (SE) forced expiratory volume in 1 s (FEV(1)) increased from 1.23 (0.11) l to 1.47 (0.13) l. The magnitude of bronchodilation was closely correlated with improved pulmonary function, particularly with that of FEV1 (r = 0.843, p < 0.001). Such correlations were significant at the fourth to the sixth generation but not at the third generation of bronchi, and the slope of the regression lines became steeper from the third to the sixth generation.
    Conclusions: Inhaled anticholinergic agents induce overall bronchodilation which is in proportion to improvements in FEV1 in patients with COPD. Bronchodilation at the distal rather than the proximal airways is the determinant of functional improvement., B M J PUBLISHING GROUP, 英語
  • Curcumin attenuates elastase- and cigarette smoke-induced pulmonary emphysema in mice
    Masaru Suzuki, Tomoko Betsuyaku, Yoko Ito, Katsura Nagai, Nao Odajima, Chinatsu Moriyama, Yasuyuki Nasuhara, Masaharu Nishimura, AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 296, 4, L614, L623, 2009年04月
    Suzuki M, Betsuyaku T, Ito Y, Nagai K, Odajima N, Moriyama C, Nasuhara Y, Nishimura M. Curcumin attenuates elastase- and cigarette smoke-induced pulmonary emphysema in mice. Am J Physiol Lung Cell Mol Physiol 296: L614-L623, 2009. First published January 23, 2009; doi:10.1152/ajplung.90443.2008.-Curcumin, a yellow pigment obtained from turmeric (Curcumina longa), is a dietary polyphenol that has been reported to possess antiinflammatory and antioxidant properties. The effect of curcumin against the development of pulmonary emphysema in animal models is unknown. The aim of this study was to determine whether curcumin is able to attenuate the development of pulmonary emphysema in mice. Nine-week-old male C57BL/6J mice were treated with intratracheal porcine pancreatic elastase (PPE) or exposed to mainstream cigarette smoke (CS) (60 min/day for 10 consecutive days or 5 days/wk for 12 wk) to induce pulmonary inflammation and emphysema. Curcumin (100 mg/kg) or vehicle was administrated daily by oral gavage 1 h and 24 h before intratracheal PPE treatment and daily thereafter throughout a 21-day period in PPE-exposed mice and 1 h before each CS exposure in CS-exposed mice. As a result, curcumin treatment significantly inhibited PPE-induced increase of neutrophils in bronchoalveolar lavage fluid at 6 h and on day 1 after PPE administration, with an increase in antioxidant gene expression at 6 h and significantly attenuated PPE-induced air space enlargement on day 21. It was also found that curcumin treatment significantly inhibited CS-induced increase of neutrophils and macrophages in bronchoalveolar lavage fluid after 10 consecutive days of CS exposure and significantly attenuated CS-induced air space enlargement after 12 wk of CS exposure. In conclusion, oral curcumin administration attenuated PPE- and CS-induced pulmonary inflammation and emphysema in mice. on March 24, 2009 ajplung. physiology. org Downloaded from, AMER PHYSIOLOGICAL SOC, 英語
  • Aging affects lipopolysaccharide-induced upregulation of heme oxygenase-1 in the lungs and alveolar macrophages
    Yoko Ito, Tomoko Betsuyaku, Chinatsu Moriyama, Yasuyuki Nasuhara, Masaharu Nishimura, BIOGERONTOLOGY, 10, 2, 173, 180, 2009年04月, [査読有り]
    Lung injuries are generally more serious and cause high mortality in aged humans and animals. Heme Oxygenase-1 (HO-1) is known to be readily inducible in alveolar macrophages (AMs) and airway epithelial cells to confer cytoprotection against oxidative stress. We thus investigated whether aging impairs the stress-induced upregulation of HO-1. In this study, we first quantified basal levels of HO-1 expression in lungs from male ICR mice of various ages. Second, young (9-11 weeks) and old (65-66 weeks) mice were subjected to intratracheal administration of lipopolysaccharide (LPS) and expression of HO-1 in the lungs was quantified at 2, 24 and 72 h. HO-1 expression in bronchiolar epithelial cells harvested by laser capture microdissection (LCM) was also specifically quantified in the two age groups. Third, we examined HO-1 expression in AMs lavaged from 22-week-old and 86-96-week-old male ICR mice in response to LPS for 24 h in vitro. We found that basal expression of HO-1 in the lungs did not differ with age. LPS-induced HO-1 upregulation was significantly impaired in the lungs of 65-66-week-old mice than in 9-11-week-old mice at 2 and 24 h, although there were no differences in the magnitude of HO-1 upregulation in bronchiolar epithelium at 2 h. LPS-induced upregulation of HO-1 was observed in AMs from 22-week-old mice (1.8-fold), but not in AMs from 86-96-week-old mice in vitro. In summary, we demonstrated age-related defects in HO-1 induction in the whole lungs and in AMs in response to LPS., SPRINGER, 英語
  • COPDの画像解析により何が明らかにされるか? (胸部の最新画像情報2009)
    長谷川 大, 南須原 康行, 臨床放射線, 54, 1, 17, 25, 2009年01月
    金原出版, 日本語
  • Catalase Expression in Pulmonary Macrophages of Smokers and Chronic Obstructive Pulmonary Disease (COPD) Patients.
    T. Inomata, T. Betsuyaku, Y. Ito, Y. Nasuhara, M. Nishimura, AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 179, 2009年, [査読有り]
    AMER THORACIC SOC, 英語, 研究発表ペーパー・要旨(国際会議)
  • 胸痛を呈し、胸膜病変の診断と病勢評価にFDG-PET (fluorodeoxyglucose-positron emission tomography) が有用であったサルコイドーシスの1例               
    日本呼吸器学会雑誌, 47, 7, 658, 662, 2009年
    速報,短報,研究ノート等(学術雑誌)
  • Matrix metalloproteinases in blood from patients with LAM
    Nao Odajima, Tomoko Betsuyaku, Yasuyuki Nasuhara, Hiromasa Inoue, Kuniaki Seyama, Masaharu Nishimura, RESPIRATORY MEDICINE, 103, 1, 124, 129, 2009年01月, [査読有り]
    Pulmonary lymphangioleiomyomatosis (LAM) is characterized by the proliferation of abnormal smooth muscle cells (LAM cells) and destruction of alveolar structure. Immunohistochemical studies suggest that excess matrix metalloproteinases (MMPs) synthesized by LAM cells function in the proteolytic mechanisms of this disease. We postulated MMP levels in the blood are elevated in LAM patients. Serum samples were collected from 36 LAM patients and 25 controls and gelatinolytic activities were semi-quantified by gelatin zymography. The reliability of serum data for MMP-9 was confirmed by the measurement of MMP-9 concentration in plasma by enzyme-linked immunosorbent assay as well as by gelatin zymography. Serum levels of MMP-9 (0.7 +/- 0.1 AU), but not MMP-2, were significantly elevated in LAM patients compared with controls (0.1 +/- 0 AU). Plasma and serum levels of MMP-9 significantly correlated. These results suggest the involvement of MMP-9 in LAM. (C) 2008 Elsevier Ltd. All rights reserved., W B SAUNDERS CO LTD, 英語
  • Down-Regulated NF-E2-Related Factor 2 in Pulmonary Macrophages of Aged Smokers and Patients with Chronic Obstructive Pulmonary Disease
    Masaru Suzuki, Tomoko Betsuyaku, Yoko Ito, Katsura Nagai, Yasuyuki Nasuhara, Kichizo Kaga, Satoshi Kondo, Masaharu Nishimura, AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 39, 6, 673, 682, 2008年12月, [査読有り]
    Pulmonary macrophages are one of the sources of various antioxidant and detoxification enzymes for which NF-E2-related factor 2 (Nrf2) is a key transcriptional factor. Although Nrf2 deficiency reportedly induces severe emphysema in mice exposed to cigarette smoke (CS), no reports have studied Nrf2 regulation in chronic obstructive pulmonary disease (COPD). In this study, Nrf2 activation in response to CS was evaluated in human alveolar macrophages, and age-related differences in CS-induced Nrf2 regulation in mouse alveolar macrophages were determined. Furthermore, Nrf2 mRNA levels in human macrophages harvested by bronchoalveolar lavage or laser capture microdissection were measured. CS induced nuclear Nrf2 accumulation and up-regulation of Nrf2 target genes without substantial changes in Nrf2 mRNA levels in human alveolar macrophages. In humans, the Nrf2 mRNA level in lavaged macrophages of young subjects (n = 14) was independent of smoking status; however, the Nrf`2 mRNA level was down-regulated in the lavaged macrophages of older current smokers (n = 14) compared with older nonsmokers (n 9) (P < 0.001). Among older subjects, the macrophage Nrf2 mRNA level was inversely correlated with oxidized glutathione and carbonylated albumin levels in bronchoalveolar lavage fluid. In mice, aging suppressed the CS-induced up-regulation of Nrf2 target genes, as well as Nrf2, in alveolar macrophages. Furthermore, the Nrf2 mRNA level was decreased in laser capture microdissection-retrieved macrophages obtained from subjects with COPD (n = 10) compared with control subjects (n = 10) (P = 0.001). In conclusion, CS induces Nrf2 activation in macrophages, and Nrf2 expression is decreased in the macrophages of older current smokers and patients with COPD., AMER THORACIC SOC, 英語
  • Diversity of protein carbonylation in allergic airway inflammation
    Katsura Nagai, Tomoko Betsuyaku, Satoshi Konno, Yoko Ito, Yasuyuki Nasuhara, Nobuyuki Hizawa, Takahito Kondo, Masaharu Nishimura, FREE RADICAL RESEARCH, 42, 11-12, 921, 929, 2008年11月, [査読有り]
    Oxidative stress is involved in asthma. This study assessed the carbonylation of sputum proteins in 23 uncontrolled adult asthmatic patients and 23 healthy controls. Carbonylated proteins (68 kDa and 53 kDa) were elevated in asthmatics when compared to controls and the 68-kDa carbonylated protein was significantly correlated with sputum eosinophilia. The kinetics of protein carbonylation in bronchoalveolar lavage fluid (BALF) were then examined in a mouse ovalbumin-induced allergic inflammation model. It was found that the carbonylation of various BALF proteins did not uniformly occur after challenge. The appearance of the 53-kDa carbonylated protein was limited within 24 h, while carbonylation of 68-kDa protein peaked at 48 h and was associated with BALF eosinophilia. Thus, it was demonstrated that the 68-kDa and 53-kDa proteins, corresponding to albumin and alpha 1-antitrypsin, respectively, were specifically carbonylated in allergic inflammation in humans and in mice and that eosinophils may play a role in mediating carbonylation of albumin., TAYLOR & FRANCIS LTD, 英語
  • 肺限局型MPO-ANCA関連血管炎と考えられた一剖検例               
    外丸 詩野, 武田 広子, 岩崎 沙理, 大塚 紀幸, 富居 一範, 笠原 正典, 清水 健一, 南須原 康行, 西村 正治, 石津 明洋, 日本病理学会会誌, 97, 2, 33, 33, 2008年09月
    (一社)日本病理学会, 日本語, 速報,短報,研究ノート等(学術雑誌)
  • Functional single nucleotide polymorphisms of the CCL5 gene and nonemphysernatous phenotype in COPD patients
    N. Hizawa, H. Makita, Y. Nasuhara, M. Hasegawa, K. Nagai, Y. Ito, T. Betsuyaku, S. Konno, M. Nishimura, EUROPEAN RESPIRATORY JOURNAL, 32, 2, 372, 378, 2008年08月, [査読有り]
    It was previously reported that the gain-of-function -28 guanine allele of the promoter single nucleotide polymorphism (SNP; cytosine to guanine substitution of nucleotide -28 (-28C > G)) in the CC chemokine ligand 5 gene (CCL5) was associated with susceptibility to late-onset asthma in patients who developed asthma at age >= 40 yrs. The clinical diagnosis of chronic obstructive pulmonary disease (COPD) includes emphysema and small airway disease, and upregulation of CCL5 has been described in the airways of patients with COPD. It was hypothesised that CCL5 has a genetic impact upon the variable expression of emphysema in patients with COPD. Patients with COPD were studied (n=267). All of the patients underwent pulmonary high-resolution computed tomography (CT), and visual scoring (CT score) was performed to determine emphysema severity. Three SNPs of CCL5 were genotyped, including -403G > A, -28C > G and 375T > C. A significant difference was found in CT score according to CCL5 genotype; the -28G allele was inversely associated with CT score. When the analysis was confined to 180 patients with bronchial reversibility of < 15%, even stronger evidence for this association was noted. Functional single nucleotide polymorphisms in the CC chemokine ligand 5 gene were associated with milder emphysema. Together with previous findings, the present study may identify the CC chemokine ligand 5 gene as part of a common pathway in the pathogenesis of late-onset asthma and chronic obstructive pulmonary disease with milder emphysema., EUROPEAN RESPIRATORY SOC JOURNALS LTD, 英語
  • ビアペネム30分点滴静注と3時間点滴静注における気管支上皮被覆液中薬物動態の解析
    菊地英毅, 山崎浩一, 菊地順子, 石坂彰敏, 南須原康行, 西村正治, 日本呼吸器学会雑誌, 46, 155, 2008年05月10日
    日本語
  • Role of basement membrane in EMMPRIN/CD147 induction in rat tracheal epithelial cells
    Takeshi Hosokawa, Tomoko Betsuyaku, Nao Odajima, Masaru Suzuki, Katsumi Mochitate, Yasuyuki Nasuhara, Masaharu Nishimura, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 368, 2, 426, 432, 2008年04月, [査読有り]
    Extracellular matrix metalloproteinase inducer (EMMPRIN) is a glycosylated transmembrane protein known to induce matrix metalloproteinases (MMPs). Although the expression of EMMPRIN is physiologically limited to fetal lung epithelium, the transcriptional regulation of this protein remains to be elucidated. We hypothesized that the interaction of epithelial cells with the basement membrane regulates EMMPRIN expression. The basement membrane has highly integrated architecture composed of specific extracellular matrix, such as laminins and type IV collagen, and exhibits multiple functions. We previously developed a structured basement membrane mimic, a synthesized basement membrane (sBM) substratum, in which laminin-111, a unique component of embryonic lungs, is incorporated. In the present study we quantified expression of EMMPRIN mRNA of rat tracheal epithelial cells cultured on sBM, laminin-111, type IV collagen, or laminin-332. EMMPRIN was upregulated on sBM and laminin-111, although this was not accompanied by MMP-9 induction. In contrast, type IV collagen and laminin-332 did not induce EMMPRIN. These findings suggest potential roles for basement membrane in the transcriptional regulation of tracheal epithelial EMMPRIN. (c) 2008 Elsevier Inc. All rights reserved., ACADEMIC PRESS INC ELSEVIER SCIENCE, 英語
  • Dual oxidase 1 and 2 expression in airway epithelium of smokers and patients with mild/moderate chronic obstructive pulmonary disease
    Katsura Nagai, Tomoko Betsuyaku, Masaru Suzuki, Yasuyuki Nasuhara, Kichizo Kaga, Satoshi Kondo, Masaharu Nishimura, ANTIOXIDANTS & REDOX SIGNALING, 10, 4, 705, 714, 2008年04月, [査読有り]
    Dual oxidase (Duox) 1 and Duox2 are important sources of hydrogen peroxide production and play a role in host defense in airways. Little is known about their regulation in association with smoking or chronic obstructive pulmonary disease (COPD). We investigated the epithelial expression of Duox1 and Duox2 in the airways of smokers, and the relationship between this expression and COPD at early stage. First, using bronchoscopy, we harvested tracheal and bronchial epithelium from individuals who have never smoked and current smokers. Duox1 expression in brushed tracheal and bronchial epithelium was significantly downregulated, whereas Duox2 was upregulated, in current smokers as compared to individuals who have never smoked. Second, laser capture microdissection and microscope-assisted manual dissection were performed in surgically resected lung tissues to collect bronchiolar epithelium and alveolar septa. Subjects with mild/moderate COPD, who were all former smokers, exhibited downregulation of bronchiolar Duox1 and Duox2 when compared to individuals who have never smoked, whereas a difference between former smokers, with and without COPD, was observed only for Duox1. Alveolar Duox1 and Duox2 expression was low and did not differ among the groups. These results imply that the airway expression of Duox1 and Duox2 is diversely associated with smoking and COPD., MARY ANN LIEBERT, INC, 英語
  • 呼吸器内科医による成人喘息診断の実態―アンケート調査の結果―               
    日本呼吸器学会雑誌, 46, 8, 601, 607, 2008年
  • Decreased airway expression of vascular endothelial growth factor in cigarette smoke-induced emphysema in mice and COPD patients
    Masaru Suzuki, Tomoko Betsuyaku, Katsura Nagai, Satoshi Fuke, Yasuyuki Nasuhara, Kichizo Kaga, Satoshi Kondo, Ichiro Hamamura, Junko Hata, Hiroshi Takahashi, Masaharu Nishimura, INHALATION TOXICOLOGY, 20, 3, 349, 359, 2008年, [査読有り]
    Vascular endothelial growth factor (VEGF) signaling is crucial for lung structure maintenance. Although VEGF deficiency plays a role in the pathogenesis of emphysema in animals, little is known about VEGF expression levels and functions, as well as VEGF receptors, in airway epithelial cells, which are in direct contact with the environment. In this study, C57BL/6J mice were exposed to cigarette smoke (CS) for short (similar to 10 days) and long (4-24 wk) time periods, and bronchiolar expressions of VEGF and its receptors VEGFR-1 and VEGFR-2 were examined. The relationships between the expressions of VEGF, VEGFR-1, and VEGFR-2 and smoking histories and/or chronic obstructive pulmonary disease (COPD) were examined in humans. The mRNA levels were quantified in bronchiolar epithelium harvested by laser capture microdissection in both mouse and human lung tissues or in human bronchial epithelium harvested by bronchoscopic brushing. The VEGF protein level was assessed by immunohistochemistry or enzyme-linked immunosorbent assay. Repeated CS exposure downregulated bronchiolar expressions of VEGF and both VEGF receptors at various time points prior to the development of emphysema. In humans, bronchiolar VEGF was significantly decreased in smokers with COPD compared to lifelong nonsmokers, as well as to smokers without COPD; however, there was no difference in bronchiolar VEGF levels between lifelong nonsmokers and smokers without COPD. On the other hand, bronchiolar VEGFR-2 was downregulated in smokers with and without COPD compared to lifelong nonsmokers. These findings suggest the association of downregulation of bronchiolar VEGF and its receptors with cigarette smoking and COPD., TAYLOR & FRANCIS INC, 英語
  • 慢性閉塞性肺疾患と中高年発症喫煙者喘息における血清総IgE値、末梢血好酸球数およびアトピー素因の比較
    清水 健一, 檜澤 伸之, 牧田 比呂仁, 今野 哲, 南須原 康行, 別役 智子, 西村 正治, 日本医師会雑誌, 137, 2, 326, 331, 2008年
    呼吸器専門医によって臨床的に診断された慢性閉塞性肺疾患(COPD)患者274例と喘息患者98例を対象に、血清総IgE値、末梢血好酸球数、更にはありふれた吸入抗原に対する特異的IgE抗体の有無で判定したアトピー性素因を比較し、COPD患者と中高年発症の喫煙喘息患者との間に相違点が認められるかを検討した。その結果、中高年発症の喫煙喘息患者が血清総IgE値、末梢血好酸球数、アトピー性素因を有する割合はCOPD患者よりも有意に高値であり、これらのアレルギー性の指標を用いることで、高い特異度で喘息病態の存在を疑うことができる可能性が示唆された。, (公社)日本医師会, 日本語
  • The realities of clinical asthma diagnosis from questionnaire results               
    Nihon Kokyuki Gakkai Zasshi, 46, 8, 601, 607, 2008年
  • Characterisation of phenotypes based on severity of emphysema in chronic obstructive pulmonary disease
    Hironi Makita, Yasuyuki Nasuhara, Katsura Nagai, Yoko Ito, Masaru Hasegawa, Tomoko Betsuyaku, Yuya Onodera, Nobuyuki Hizawa, Masaharu Nishimura, THORAX, 62, 11, 932, 937, 2007年11月, [査読有り]
    Background: Airflow limitation in chronic obstructive pulmonary disease ( COPD) is caused by a mixture of small airway disease and emphysema, the relative contributions of which may vary among patients. Phenotypes of COPD classified purely based on severity of emphysema are not well defined and may be different from the classic phenotypes of "pink puffers'' and "blue bloaters''.
    Methods: To characterise clinical phenotypes based on severity of emphysema, 274 subjects with COPD were recruited, excluding those with physician-diagnosed bronchial asthma. For all subjects a detailed interview of disease history and symptoms, quality of life (QOL) measurement, blood sampling, pulmonary function tests before and after inhalation of salbutamol (0.4 mg) and high- resolution CT scanning were performed.
    Results: Severity of emphysema visually evaluated varied widely even among subjects with the same stage of disease. No significant differences were noted among three groups of subjects classified by severity of emphysema in age, smoking history, chronic bronchitis symptoms, blood eosinophil count, serum IgE level or bronchodilator response. However, subjects with severe emphysema had significantly lower body mass index (BMI) and poorer QOL scores, evaluated using St George's Respiratory Questionnaire (SGRQ), than those with no/mild emphysema (mean ( SD) BMI 21.2 (0.5) vs 23.5 (0.3) kg/m(2), respectively; SGRQ total score 40 (3) vs 28 (2), respectively; p < 0.001 for both). These characteristics held true even if subjects with the same degree of airflow limitation were chosen.
    Conclusions: The severity of emphysema varies widely even in patients with the same stage of COPD, and chronic bronchitis symptoms are equally distributed irrespective of emphysema severity. Patients with the phenotype in which emphysema predominates have lower BMI and poorer health-related QOL., B M J PUBLISHING GROUP, 英語
  • Loss of caveolin-1 in bronchiolization in lung fibrosis
    Nao Odajima, Tomoko Betsuyaku, Yasuyuki Nasuhara, Masaharu Nishimura, JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 55, 9, 899, 909, 2007年09月
    Bronchiolization is a key process in fibrosing lung in which the proliferative status of bronchiolar epithelium changes, leading to abnormal epithelial morphology. Within the context that caveolin-1 acts to suppress epithelial proliferation, we postulated that stimulating epithelial injury would lead to caveolin-1 downregulation and encourage proliferation. The present study evaluates the expression of caveolin-1, especially in bronchiolization, in CS7BL/6J mice with bleomycin-induced lung fibrosis and in various types of re-epithelialization in human interstitial pneumonias (IPs). Immunohistochemically, levels of caveolin-1 decreased in the bronchiolar epithelium of mice treated with bleomycin. Levels of caveolin-1 mRNA in the whole lung were decreased at 7 and 14 days. Caveolin-1 mRNA was also decreased in laser-capture microdissection- retrieved bronchiolar epithelial cells at 7 days. Among patients with 12 IPs, including four usual IPs (UIPs) and eight nonspecific IPs (NSIPs), whole lung caveolin-1 was significantly decreased compared with 12 controls at both mRNA and protein levels. By scoring immunointensity, caveolin-1 was significantly reduced in bronchiolization and squamous metaplasia as well as in bronchiolar epithelium in 23 IPs (12 UIPs and 11 NSIPs) compared with bronchiolar epithelium from seven controls. These data suggested that loss of caveolin-1 is associated with abnormal re-epithelialization in lung fibrosis., HISTOCHEMICAL SOC INC, 英語
  • Increase in soluble CD138 in bronchoalveolar lavage fluid of multicentric Castleman's disease
    Masaru Hasegawa, Tomoko Betsuyaku, Nobuya Yoshida, Yasuyuki Nasuhara, Ichiro Kinoshita, Satoshi Ohta, Tomoo Itoh, Pyong Woo Park, Masaharu Nishimura, RESPIROLOGY, 12, 1, 140, 143, 2007年01月, [査読有り]
    Multicentric Castleman's disease (MCD) is a rare and often incurable lymphoproliferative disorder. It is typically a systemic illness, but occasionally manifests primarily as a pulmonary parenchymal disease with massive infiltration of CD138 (syndecan-1)-positive plasma cells. This is the first report to demonstrate a marked elevation of soluble CD138, despite the absence of plasma cells, in BAL fluid in an MCD patient with pulmonary involvement. This finding suggests that the quantitative measurement of soluble CD138 in BAL fluid may reflect plasma cell infiltration and disease activity in the lungs of patients with MCD., BLACKWELL PUBLISHING, 英語
  • リウマチ性多発筋痛症寛解後非特異的間質性肺炎, 自己免疫性溶血性貧血を合併した1例
    中舘 恵, 南須原 康行, 濱田 邦夫, 西村 正治, 日本呼吸器学会雑誌 = The journal of the Japanese Respiratory Society, 44, 11, 864, 868, 2006年11月10日
    日本語
  • Airflow limitation and airway dimensions in chronic obstructive pulmonary disease
    M Hasegawa, Y Nasuhara, Y Onodera, H Makita, K Nagai, S Fuke, Y Ito, T Betsuyaku, M Nishimura, AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 173, 12, 1309, 1315, 2006年06月, [査読有り]
    Rationale: Chronic obstructive pulmonary disease (COPD) is characterized by airflow limitation caused by emphysema and/or airway narrowing. Computed tomography has been widely used to assess emphysema severity, but less attention has been paid to the assessment of airway disease using computed tomography.
    Objectives: To obtain longitudinal images and accurately analyze short axis images of airways with an inner diameter >= 2 mm located anywhere in the lung with new software for measuring airway dimensions using curved multiplanar reconstruction.
    Methods: In 52 patients with clinically stable COPD (stage I, 14; stage II, 22; stage III, 14; stage IV, 2), we used the software to analyze the relationship of the airflow limitation index (FEV1, % predicted) with the airway dimensions from the third to the sixth generations of the apical bronchus (B1) of the right upper lobe and the anterior basal bronchus (88) of the right lower lobe. Measurements and Main Results: Airway luminal area (Ai) and wall area percent (WA%) were significantly correlated with FEV1 (% predicted). More importantly, the correlation coefficients (r) improved as the airways became smaller in size from the third (segmental) to sixth generations in both bronchi (Ai: r = 0.26, 0.37, 0.58, and 0.64 for 81; r = 0.60, 0.65, 0.63, and 0.73 for BB).
    Conclusions: We are the first to use three-dimensional computed tomography to demonstrate that airflow limitation in COPD is more closely related to the dimensions of the distal (small) airways than proximal (large) airways., AMER THORACIC SOC, 英語
  • 【抗菌薬サイクリングvsミキシング 耐性菌対策としての抗菌薬使用への介入】 ICUにおける抗菌薬サイクリング               
    松田 直之, 秋沢 宏次, 南須原 康行, 石黒 信久, 奥 直子, 早川 峰司, 澤村 淳, 石川 岳彦, 亀上 隆, 西村 正治, 丸藤 哲, Progress in Medicine, 25, 9, 2329, 2336, 2005年09月
    (株)ライフ・サイエンス, 日本語
  • 目でみる症例 特発性器質化肺炎(COP/BOOP)
    小田島 奈央, 南須原 康行, 西村 正治, 内科, 96, 1, 147, 151, 2005年07月
    南江堂, 日本語
  • 「Q熱に伴う器質化肺炎の1例」
    小野 江和之, 南須原 康行, 笠原 郁美, 檜澤 伸之, 西村 正治, 上野 弘志, 村松 康和, 森田 千春, 田村 豊, 『日内会誌』, 94, 5, 961, 963, 2005年
    症例は69歳女性.特発性器質化肺炎としてステロイド治療を開始し,自他覚所見は速やかに改善した.しかし,経過中行った検索にてCoxiella burnetiiに対する血清抗体価上昇,血液PCR陽性であったため, Q熱が器質化肺炎の原因と考えられた. Q熱については,診断法が一般的でなく市中肺炎の原因としても見逃されていることが多いとされており,特発性器質化肺炎と診断されている症例の中に, Q熱によって引き起こされている症例が少なからず存在する可能性がある., The Japanese Society of Internal Medicine, 日本語, 速報,短報,研究ノート等(学術雑誌)
  • 「気管支肺胞洗浄所見の変化を追跡したgefitinibによる間質性肺炎の1例」               
    『日呼吸会誌』, 43, 466, 470, 2005年
    速報,短報,研究ノート等(学術雑誌)
  • 「咳喘息に対する吸入ステロイド単独療法とプロカテロール併用療法の比較」               
    『呼吸』, 24, 65, 70, 2005年
  • Nagai K,Betsuyaku T,Ito Y,Nasuhara Y,Nishimura M.: “Decrease of vascular endothelial growth factor in macrophages from long-team smokers” ,Eur Respir J,25:626-633 (2005)*               
    2005年, [査読有り]
  • Ito Y,Betsuyaku T,Nagai K,Nasuhara Y,Nishimura M.: “Expression of pulmonary VEGF family declines with age and is further down-regulated in lipopolysaccharide(LPS)-induced lung injury” ,Exp Gerontol,40:315-323 (2005)
    Y Ito, T Betsuyaku, K Nagai, Y Nasuhara, M Nishimura, EXPERIMENTAL GERONTOLOGY, 40, 4, 315, 323, 2005年, [査読有り]
    Vascular endothelial growth factor (VEGF) is a survival factor in endothelial cells and a promoter of angiogenesis that reportedly plays a pivotal role protecting against injury. In aged humans and animals, lung injuries are generally more serious and cause higher mortality. We thus hypothesized that the expression of VEGF and its related molecules in the lung declines with age. In this study, we first examined the expression of VEGF family (VEGF-A, -B, -C and -D), VEGF-A isoforms (VEGF120, 164, 188), and VEGF-specific receptors (VEGFR-1: Flt-1: VEGFR-2: Flk-1 and VEGFR-3: Flt-4) by quantitative RT-PCR in lungs front young and old mice. Expression of all these except for VEGF-D was significantly lower in old mice than in young mice. We then subjected young and old mice to lipopolysaccaride (LPS)-induced lung injury. Old animals demonstrated poor survival and prolonged lung inflammation when compared with young counterparts. At 24 and 72 h after intratracheal LPS administration, expression of the examined factors was down-regulated in the lungs irrespective of age. In conclusion. pulmonary expression of the VEGF family and their receptors declines with age, and is further down-regulated in LPS-induced lung injury, although the mechanism of age- and/or injury-related clown-regulation of VEGF remains unknown. (c) 2005 Elsevier Inc. All rights reserved., PERGAMON-ELSEVIER SCIENCE LTD, 英語
  • A case of paclitaxel-induced pneumonitis
    Natsuko Taniguchi, Naofumi Shinagawa, Ichiro Kinoshita, Yasuyuki Nasuhara, Koichi Yamazaki, Etsuro Yamaguchi, Hirotoshi Akita, Masaharu Nishimura, Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society, 42, 2, 158, 163, 2004年
    A 79-year-old woman with small-cell lung cancer was treated weekly with paclitaxel after previous treatment with carboplatin and etoposide. Within the first course of paclitaxel, chest radiography and CT revealed thickening of the bronchovascular bundle and interlobular septa, and infiltrates in both lung fields. A marked increase in the number of lymphocytes was found on bronchoalveolar lavage (BAL). Microorganisms such as Cytomegalovirus, Mycobacteria, and Pneumocystis carinii were absent from the BAL fluid. Interstitial infiltration was partially improved simply by stopping paclitaxel administration, without the need for any additional therapy. Drug-induced pneumonitis caused by paclitaxel was diagnosed on the basis of the clinical course and findings, although a drug lymphocyte stimulation test yielded negative results for paclitaxel. Interstitial infiltrates on imaging, symptoms and arterial blood gas results improved with administration of oral prednisolone. The possibility of pneumonitis induced by paclitaxel should be considered even in cases without interstitial lung disease., 日本語, 書評論文,書評,文献紹介等
  • 「パクリタキセル投与との関連が示唆された薬剤性肺炎の1例」               
    『日呼吸会誌』, 42, 158, 163, 2004年
    速報,短報,研究ノート等(学術雑誌)
  • Kobayashi M,Nasuhara Y,Betsuyaku T,Shibuya E,Tanino Y,Tanino M,Takamura K,Nagai K,Hosokawa T,Nishimura M.:“Effect of low-dose theophylline on airway inflammation in COPD”,Respirology,9:249-254 (2004)*               
    2004年, [査読有り]
  • Takamura K,Nasuhara Y,Kobayashi M,Betsuyaku T,Tanino Y,Kinoshita I,Yamaguchi E,Matsukura S,Schleimer RP,Nishimura M.:“Retinoic acid inhibits interleukin-4-induced eotaxin production in a human bronchial epithelial cell line”,Am J Physiol Lung Cell Mol ・・・               
    2004年, [査読有り]
    Takamura K,Nasuhara Y,Kobayashi M,Betsuyaku T,Tanino Y,Kinoshita I,Yamaguchi E,Matsukura S,Schleimer RP,Nishimura M.:“Retinoic acid inhibits interleukin-4-induced eotaxin production in a human bronchial epithelial cell line”,Am J Physiol Lung Cell Mol Physiol,286:777-785 (2004)*
  • Fuke S,Betsuyaku T,Nasuhara Y,Morikawa T,Katoh H,Nishimura M.:“Chemokines in Bronchiolar Epithelium in the Development of Chronic Obstructive Pulmonary Disease”,Am J Respir Cell Mol Biol,31:405-412 (2004)*               
    2004年, [査読有り]
  • Catley MC,Cambridge LM,Nasuhara Y,Itoh K,Chivers JE,Beaton A,Holden NS,Bergmann MW,Barnes PJ,Newton R.:“Inhibitors of Protein Kinase C (PKC) Prevent Activated Transcription;Role of events down stream of NF-κB DNA binding”,J Biol Chem,279:18457-18466 (2・・・               
    2004年, [査読有り]
    Catley MC,Cambridge LM,Nasuhara Y,Itoh K,Chivers JE,Beaton A,Holden NS,Bergmann MW,Barnes PJ,Newton R.:“Inhibitors of Protein Kinase C (PKC) Prevent Activated Transcription;Role of events down stream of NF-κB DNA binding”,J Biol Chem,279:18457-18466 (2004)*
  • Betsuyaku T,Kuroki Y,Nagai K,Nasuhara Y,Nishimura M.:“Effects of ageing and smoking on SP-A and SP-D levels in bronchoalveolar lavage fluid”,Eur Respir J,24:964-970 (2004)*               
    2004年, [査読有り]
  • 「喘息におけるβ刺激薬」               
    『International Review of Asthma』, 6, 30, 36, 2004年
    記事・総説・解説・論説等(学術雑誌)
  • 6. RS_3PE症候群に肺扁平上皮癌を合併した1例(第29回日本肺癌学会北海道支部会)(支部活動)
    菅 正之, 山崎 浩一, 木下 一郎, 濱田 邦夫, 南須原 康行, 西村 正治, 天崎 吉晴, 秋田 弘俊, 肺癌, 43, 7, 1047, 1047, 2003年12月30日
    日本肺癌学会, 日本語
  • 上肺の線維化に合併したアスペルギルス感染と血中, BAL液中SP-A, SP-Dの経過
    福家 聡, 別役 智子, 大泉 聡史, 南須原 康行, 斉藤 拓志, 山口 悦郎, 西村 正治, 日本呼吸器学会雑誌 = The journal of the Japanese Respiratory Society, 41, 3, 196, 201, 2003年03月10日
    日本語
  • Betsuyaku T, Tanino M, Nagai K, Nasuhara Y, Nishimura M, Senior RM. Related Articles, Links Extracellular matrix metalloproteinase inducer is increased in smokers' bronchoalveolar lavage fluid. Am J Respir Crit Care Med. 2003 Jul 15;168(2):222-7.*               
    2003年, [査読有り]
  • Elevated serum KL-6 concentrations in patients with diabetes mellitus
    T Takahashi, K Takamura, S Sakaue, J Ishii, H Yokouchi, Y Nasuhara, JOURNAL OF DIABETES AND ITS COMPLICATIONS, 16, 5, 352, 358, 2002年09月
    To clarify the influence of blood glucose level or diabetes mellitus on serum KL-6, a mucin-like glycoprotein, concentrations, they were measured against 176 diabetic subjects, including receiving insulin (INS) group (n = 54), oral antidiabetics (OAD) group (n = 78), and diet and exercise (D&E) group (n = 44). Serum KL-6 concentrations in the diabetic subjects were significantly greater than those in the normal healthy control subjects (643.0 +/- 32.7 U/ml, 206.5 +/- 6.1 U/ml, P<.0001, respectively), and those in the INS and OAD groups were significantly greater than those in the D&E group (708.2 +/- 66.9, 691.7 +/- 51.9, and 476.6 +/- 34.9 U/ml, P<.05, P<.05, respectively). Serum KL-6 concentrations did not correlate with urine KL-6 concentrations (n=73, r=-044, P=.74). Immunohistochemical staining of the diabetic kidneys with a monoclonal antibody to KL-6 antigen showed positive immunoreactivity on Henle's loop, renal tubules, and epithelial cells in Bowman's space of sclerosing glomerulus. In conclusion, diabetes mellitus or complications of diabetes mellitus resulted in serum KL-6 elevation regardless of serum glucose level, but serum KL-6 concentrations were not influenced despite control of diabetes mellitus. (C) 2002 Elsevier Science Inc. All rights reserved., ELSEVIER SCIENCE INC, 英語
  • Takahashi, T., Ohtsuka, Y., Munakata, Y., Nasuhara, Y., Kamachi-Satoh, A., Homma, Y., Kawakami Y.:"Occurence of Farmer's Lung Disease is relevant to meteorological conditions: A 20-year follow-up field survey analysis", Am J Ind Med, 41:506-513(2002)*               
    2002年, [査読有り]
  • Kamachi, A., Nasuhara, Y., Nishimura, M., Takahashi, T., Homma, Y., Ohtsuka, Y., Munakata, M.: "Dissociation between airway responsiveness to methacholine and responsiveness to antigen", Eur Respir J, 19:76-83 (2002)*               
    2002年, [査読有り]
  • Enhancement of goblet cell hyperplasia and airway hyperresponsiveness by salbutamol in a rat model of atopic asthma
    A Kamachi, M Munakata, Y Nasuhara, M Nishimura, Y Ohtsuka, M Amishima, T Takahashi, Y Homma, Y Kawakami, THORAX, 56, 1, 19, 24, 2001年01月
    Background-Goblet cell hyperplasia (GCH) is a prominent feature in animal models of atopic asthma produced by immunisation and following multiple challenges with antigens. The aim of this study was to examine the effect of a beta (2) agonist on the development of GCH induced by the immune response.
    Methods-Brown Norway rats were immunised and challenged with an aerosol of ovalbumin for four weeks. Salbutamol (0.5 mg/kg/day) or vehicle was continuously delivered for the four weeks using a subcutaneously implanted osmotic minipump. The density of goblet cells, other morphological changes, and airway responsiveness to methacholine were evaluated 24 hours after the final challenge.
    Results-Treatment with salbutamol induced a more than twofold increase in the mean (SE) number of goblet cells (53.7 (7.3) vs 114.5 (11.8) cells/10(3) epithelial cells, p<0.01) while it did not significantly influence airway wall thickening and eosinophilic infiltration. Airway responsiveness to methacholine expressed as the logarithmic value of the concentration of methacholine required to generate a 50% increase in airway pressure (logPC(150)Mch) was also enhanced by the <beta>(2) agonist (-0.56 (0.21) vs -0.95 (0.05), p<0.05). Additional experiments revealed that the same dose of the <beta>(2) agonist alone did not cause GCH in non-immunised rats and that the enhancement of GCH by salbutamol was completely abolished by simultaneous treatment with methylprednisolone (0.5 mg/kg/day).
    Conclusions-These data suggest that salbutamol enhances goblet cell hyperplasia and airway hyperresponsiveness in this rat model of atopic asthma., BRITISH MED JOURNAL PUBL GROUP, 英語
  • Effect of an oral β2-adrenoceptor agonist in a patient with idiopathic interstitial pneumonia
    T. Takahashi, Y. Nasuhara, K. Takamura, Y. Kawakami, Allergology International, 50, 1, 109, 111, 2001年, [査読有り]
    A 63-year-old man was referred to our hospital because of a dry cough. His chest roentgenogram revealed ground-glass opacities and honeycomb formations bilaterally in the lower lung fields. Pulmonary function tests showed a depleted lung volume and decreased arterial oxygen tension. He was clinically diagnosed as having idiopathic interstitial pneumonia (IIP). A β2-adrenoceptor agonist was administrated because the patient's symptoms improved after its inhalation. Following treatment with an oral β2-adrenoceptor agonist, the dry cough disappeared, lung function tests remained unchanged and an improvement in arterial oxygen tension was observed. Although β2-adrenoceptor agonist therapy does not improve disease activity or progression in patients with IIP, its use may mitigate symptoms associated with the disease., Blackwell Publishing, 英語
  • Kamachi,A., Munakata,M., Nasuhara,Y., Nishimura,M., Ohtsuka,Y., Kawakami,Y.:"Enhancement of gblet cell hyperplasia and airway hypereponsiveness by salbutamol in a rat model of atopic asthma", Thorax,56:19-24(2001)*               
    2001年, [査読有り]
  • Meja,KK., Seldon,PM., Nasuhara,Y., Ito,K., Barnes,PJ., Lindsay,MA., Giembycz,MA. "p38 MAP kinase and MKK-1 co-operate in the generation of GM-CSF from LPS-stimulated human monocytes by an NF-kappaB-independent mechanism", Br J Pharmacol, 131:1143-1153(・・・
    KK Meja, PM Seldon, Y Nasuhara, K Ito, PJ Barnes, MA Lindsay, MA Giembycz, BRITISH JOURNAL OF PHARMACOLOGY, 131, 6, 1143, 1153, 2000年11月, [査読有り]
    Meja,KK., Seldon,PM., Nasuhara,Y., Ito,K., Barnes,PJ., Lindsay,MA., Giembycz,MA. "p38 MAP kinase and MKK-1 co-operate in the generation of GM-CSF from LPS-stimulated human monocytes by an NF-kappaB-independent mechanism", Br J Pharmacol, 131:1143-1153(2000)*, NATURE PUBLISHING GROUP, 英語
  • Extracellular signal-regulated kinase 1/2 control Ca2+-independent force development in histamine-stimulated bovine tracheal smooth muscle
    A Koch, Y Nasuhara, PJ Barnes, MA Lindsay, MA Giembycz, BRITISH JOURNAL OF PHARMACOLOGY, 131, 5, 981, 989, 2000年11月, [査読有り]
    1 The role of extracellular signal-regulated kinase (ERK)-1 and ERK-2 in controlling histamine-induced tone in bovine trachealis was investigated. PD 098059, an inhibitor of mitogen-activated protein kinase kinase (MKK)-1, had no effect on the histamine concentration-response relationship that described contraction. However, in the presence of EGTA, PD 098059 produced a parallel 5 fold rightwards shift of the histamine concentration-response curve without reducing the maximum response. The Pz-adrenoceptor agonist, procaterol, also displaced the histamine-concentration response curve to the right but the effect was much greater than that evoked by PD 098059, noncompetitive and seen in the absence and presence of EGTA.
    2 A low basal level of pERK-1 and pERK-2 was always detected in untreated trachealis, which was significantly higher in EGTA-treated tissues and inhibited by PD 098059 and procaterol. Histamine markedly enhanced the phosphorylation of ERK-1 and ERK-2 by a mechanism that was also enhanced by EGTA and significantly attenuated by procaterol and PD 098059.
    3 Neither cholera toxin nor Sp-8-Br-cAMPS mimicked the ability of procaterol to dephosphorylate ERK. Similarly, neither pertussis toxin (PTX) nor Rp-8-Br-cAMPS, an inhibitor of cyclic AMP-dependent protein kinase (PKA), affected basal pERK levels or antagonized the inhibitory effect of procaterol.
    4 These data implicate the MKK-1/ERK signalling cascade in Ca2+-independent, histamine-induced contraction of bovine trachealis. In addition, the ability of procaterol to dephosphorylate ERK in an Rp-8-Br-cAMPS- and PTX-insensitive manner suggests that this may contribute to the anti-spasmogenic activity of beta (2)-adrenoceptor agonists by activating a novel PKA-independent pathway., NATURE PUBLISHING GROUP, 英語
  • Hisada,T., Salmon,M., Nasuhara,Y., Chung,KF. "Involvement of haemooxygenase-1 in ozone-induced airway inflammation and hyperresponsiveness",Eur J Pharmacol, 399:229-234(2000)*               
    2000年, [査読有り]
    英語
  • Cysteinyl-leukotrienes partly mediate eotaxin-induced bronchial hyperresponsiveness and eosinophilia in IL-5 transgenic mice
    T Hisada, M Salmon, Y Nasuhara, KF Chung, AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 160, 2, 571, 575, 1999年08月, [査読有り]
    Eotaxin, a selective chemoattractant for eosinophils, induces lung eosinophilia and bronchial hyperresponsiveness (BHR) when administered intratracheally to interleukin-5 (IL-5) transgenic mice. We determined whether these effects of eotaxin were mediated through the production of cysteinyl-leukotrienes. IL-5 transgenic mice were administered eotaxin (5 mu g) intratracheally after pretreatment with either diluent or a selective 5-lipoxygenase inhibitor SB210661 or a cysteinyl-leukotriene receptor antagonist, pranlukast. Twenty-four hours later, bronchial responsiveness to acetylcholine was measured and the degree of eosinophil influx was determined in bronchoalveolar lavage fluid (BALF) or in lung tissue. Both pranlukast and 5B210661 significantly attenuated BHR induced by eotaxin with logPC(50), which is the concentration of acetylcholine needed to increase baseline insufflation pressure by 50%, from -0.43 +/- 0.16 to 0.39 +/- 0.10 and from -0.22 +/- 0.10 to 0.53 +/- 0.10, respectively (p < 0.05). There was also a significant attenuation of the eosinophil counts in BALF and in airways. BALF levels of leukotriene C-4 (LTC4) showed a significant increase after eotaxin from 23.9 +/- 6.7 to 165.0 +/- 35.0 pg/ml (p < 0.05) but were partially suppressed by both SB210661 (71.2 +/- 21.0) and pranlukast (62.7 +/- 11.5). Concentrations of LTB4 were not significantly changed. We conclude that eotaxin-induced effects in the airways of IL-5 transgenic mice are partly mediated by the activation of 5-lipoxygenase enzyme leading to the generation of cysteinyl-leukotrienes., AMER LUNG ASSOC, 英語
  • Adcock,I.M., Nasuhara,Y., Stevens,D.A., Barnes,P.J.: "Ligand-induced differentiation of glucocorticoid receptor (GR) transrepression and transactivation: preferential targetting of NF-kB and lack of I-kB involvement", Br.J.Pharmacol., 127:1003-1011 (19・・・
    IM Adcock, Y Nasuhara, DA Stevens, PJ Barnes, BRITISH JOURNAL OF PHARMACOLOGY, 127, 4, 1003, 1011, 1999年06月, [査読有り]
    Adcock,I.M., Nasuhara,Y., Stevens,D.A., Barnes,P.J.: "Ligand-induced differentiation of glucocorticoid receptor (GR) transrepression and transactivation: preferential targetting of NF-kB and lack of I-kB involvement", Br.J.Pharmacol., 127:1003-1011 (1999)*, STOCKTON PRESS, 英語
  • Hisada,T., Adcock,I.M., Nasuhara,Y., Salmon,M., Huang,T.J., Chung,K.F.: "Inhibition of ozone-induced lung neutrophilia and nuclear factor-kappa B binding activity by vitamin A in rat", Eur.J.Pharmacol., 377:63-68 (1999)*               
    1999年, [査読有り]
    英語
  • Nasuhara,Y., Adcock,I.M., Catley,M., Barnes,P.J., Newton,R.: "Differential IkB kinase activation and IkBa degradation by interleukin-1b and tumor necrosis factor-a in human U937 monocytic cells", J.Biol.Chem., 274:571-575 (1999)*               
    1999年

所属学協会

  • 2021年06月 - 2023年05月
    日本結核・非結核性抗酸菌症学会               
  • 日本医療マネジメント学会               
  • 医療の質・安全学会               
  • 日本内科学会               
  • 日本呼吸器学会               
  • 日本感染症学会               
  • American College of Physicians               

Works(作品等)

  • 第61回日本アレルギー学会秋季学術大会               
    2011年
  • 第51回日本呼吸器学会学術講演会4               
    2011年
  • 第51回日本呼吸器学会学術講演会3               
    2011年
  • 第51回日本呼吸器学会学術講演会2               
    2011年
  • 第51回日本呼吸器学会学術講演会1               
    2011年
  • 第60回日本アレルギー学会秋季学術大会               
    2010年
  • 第257回日本内科学会北海道地方会               
    2010年
  • 第255回日本内科学会北海道地方会               
    2010年
  • 第50回日本呼吸器学会学術講演会3               
    2010年
  • 第50回日本呼吸器学会学術講演会1 English mini symposium               
    2010年
  • 第107回日本内科学会総会               
    2010年
  • 第50回日本呼吸器学会学術講演会2 教育講演10               
    2010年
  • 第50回日本呼吸器学会学術講演会4               
    2010年
  • 第99回日本呼吸器学会北海道地方会               
    2010年
  • 第254回日本内科学会北海道地方会               
    2010年
  • 第2回呼吸機能イメージング2               
    2010年
  • 第2回呼吸機能イメージング研究会1               
    2010年
  • 第252回日本内科学会北海道地方会発表               
    2009年
  • 第251回日本内科学会北海道地方会発表               
    2009年
  • 第49回日本呼吸器学会学術講演会発表 5               
    2009年
  • 第49回日本呼吸器学会学術講演会発表 4               
    2009年
  • 第49回日本呼吸器学会学術講演会発表 3               
    2009年
  • 第49回日本呼吸器学会学術講演会発表 2               
    2009年
  • 第49回日本呼吸器学会学術講演会発表 1               
    2009年
  • 第250回日本内科学会北海道地方会発表 2               
    2009年
  • 第250回日本内科学会北海道地方会発表 1               
    2009年
  • 第97回日本呼吸器学会北海道地方会発表 2               
    2009年
  • 第97回日本呼吸器学会北海道地方会発表 1               
    2009年

共同研究・競争的資金等の研究課題

  • 人工知能技術を利用した医用画像診断支援システムの倫理リスクマネジメント手法の研究
    科学研究費助成事業
    2020年04月01日 - 2021年03月31日
    平田 雄一, 平田 健司, 南須原 康行, 白土 博樹
    本研究は、将来的に重要性が増すと予想される人工知能技術を利用した医用画像診断支援システムの倫理リスクを具体化するための新しいリスクマネジメント手法の構築を試み、人工知能技術を利用した医用画像診断支援システムの倫理リスクの低減策の検討を詳細に深く行えるようにすることを目的とした。
    具体的には、本研究では、医学物理学の放射線治療分野や放射線安全管理分野において、既に活用されている複雑なシステムを、システムの要素(コンポーネント)間の入力と出力により決定される制御関係の安全性に着目して解析する安全解析手法であるSTAMP(System Theoretic Accident Model and Processes)を、人工知能技術を利用した医用画像診断支援システムの倫理リスクのリスクマネジメントに応用した。
    2020年度は、新しい倫理リスク・マネジメント・モデルを、医用画像に関する倫理リスク事項のネットワークを高速に処理するために本研究で購入した高速データ処理が可能な高性能ワークステーション上に実装されたSTAMPのモデリングツールであるSTAMP Workbenchを基盤とした新しい倫理リスク・モデリング・システムにより構築した。
    その結果、本研究で構築した、STAMP Workbenchを基盤とした、人工知能技術を利用した医用画像診断支援システムの新しい倫理リスクマネジメント手法は、放射線治療における事故防止のための強力なツールとなりえることが明らかになった。
    そして、日本放射線腫瘍学会第33回学術大会において、本研究の分担者全員と共同して上記研究結果を発表した。
    日本学術振興会, 基盤研究(C), 北海道大学, 20K12708
  • 高信頼性内視鏡外科医育成のための継続的教育モデルの構築
    科学研究費助成事業
    2017年04月01日 - 2020年03月31日
    安部 崇重, 南須原 康行, 篠原 信雄
    ブタ臓器を用いた腹腔鏡手術手技トレーニングモデルを開発した。参加者は3つのタスク(1: 大動脈周囲の組織剥離, 2: 腎動脈の剥離とヘモロックを用いた血管処理, 3: 腎実質縫合)を行い、トレーニングの録画動画を2名の技術認定医が評価した。医師40名、医学生14名のデータに関して開発したモデルの良好なconstruct validityを確認した。またVirtual reality (VR)シミュレーターを用いて、腹腔鏡下左腎摘除術シナリオのvalidation studyを行った。33名が参加し、VRシミュレーターの良好なconstruct validityを確認した。
    日本学術振興会, 基盤研究(C), 北海道大学, 17K08897
  • インシデント報告、ニアミス報告を利用した高信頼性手術チームの醸成に関する研究
    科学研究費助成事業
    2014年04月01日 - 2017年03月31日
    安部 崇重, 南須原 康行, 篠原 信雄
    公益財団法人日本医療機能評価機構医療事故情報収集等事業による公開データに関して、腹腔鏡/胸腔鏡手術関連の報告540件から、746件のインシデントを抽出した。術式別の比較では、腹腔鏡/腹腔鏡補助手術(L群)582件、胸腔鏡/胸腔鏡補助手術(T群)159件、腹腔鏡+胸腔鏡手術5件のインシデントを認めた。他臓器損傷、異物遺残、医療機器の不良/故障、大量出血、血管等の誤認、血管損傷の報告が多かった。L群/T群の比較では、他臓器損傷, 大量出血, 血管損傷で差を認めた。
    日本学術振興会, 基盤研究(C), 北海道大学, 26460853
  • 気管支喘息、COPDの病態における組織因子(TF)、第7因子(F7)の関与
    科学研究費助成事業
    2011年 - 2013年
    今野 哲, 伊佐田 朗, 南須原 康行
    2種類のマウス喘息モデルにおいて、気管支肺胞洗浄液(BALF)中、全肺組織において、組織因子(TF)、第VII因子の発現が亢進していることを確認した。更には、同モデルにおいて、TF-第VII因子阻害作用を有するFVIIaiを腹腔内投与したところ、BALF中の好酸球細胞数の減少、OVA特異的IgE抗体の低下、及び気道過敏性の改善を確認した。以上の結果は、FVIIaiの気管支喘息の新たな治療法の可能性を示唆するものと考えられた。
    遺伝子多型研究においては、症例(喘息)-対象研究において、凝固系カスケードに関連する種々の遺伝子(TF,F2R,CC16,CAT)に存在するのSNPsと気管支喘息との関連を見出した。
    日本学術振興会, 基盤研究(C), 北海道大学, 23591110
  • 難治性喘息に対する創薬への挑戦-新規NF-kB阻害薬(DHMEQ)の可能性-
    科学研究費助成事業
    2009年 - 2011年
    西村 正治, 藤堂 省, 南須原 康行, 今野 哲
    新規NF-kB阻害薬であるDHMEQは、種々の慢性炎症性疾患モデルにおける効果が報告されている。本研究では、マウス喘息モデルにおいて、DHMEQは、好酸球性気道炎症、気道線維化を有意に抑制することが見出された。更には、in vitroを用いた系において、気道上皮細胞からのケモカインの抑制、Th2細胞からのサイトカイン産生を抑制することが示された。DHMEQは、気管支喘息における新規治療薬となる可能性が示唆された。
    日本学術振興会, 挑戦的萌芽研究, 北海道大学, 21659206
  • 大規模コホート研究による難治性気道疾患の病態解明と個別化治療への展開
    科学研究費助成事業
    2009年 - 2011年
    西村 正治, 今野 哲, 南須原 康行, 牧田 比呂仁
    慢性閉塞性肺疾患(COPD)患者における1秒量の経年変化は、必ずしもすべての症例で進行性ではなく、5年間にわたり1秒量経年変化が維持される症例も認め、症例により様々である。この結果は、COPDが常に進行性であるという、疾患概念を覆すものであり、治療の重要性を示す。
    また、1秒量経年変化が急速に低下する群では、気腫病変の重症度が、気流閉塞の重症度とは独立した寄与因子であった。この結果は、今後の臨床研究において新しい病型分類に基づいた評価、解析が必要性を示している。
    日本学術振興会, 基盤研究(B), 北海道大学, 21390253
  • 慢性喫煙と加齢が肺胞マクロファージのアポトーシス細胞貪食能に与える影響
    科学研究費助成事業
    2008年 - 2010年
    南須原 康行, 伊藤 洋子, 別役 智子
    マクロファージの細胞表面に発現するアポトーシス細胞の認識/貪食に関わる受容体が、喫煙や加齢の影響でどのように修飾を受けるのかを検討した。非喫煙者では加齢により、肺胞マクロファージ(AM)のhosphatidylserine receptor(PSR)やscavenger receptor A(SR-A)の発現は上昇したが、中高年では喫煙者のPSR, SR-A発現は同年齢の非喫煙者と比較し低値であった。また、分化誘導したマクロファージ様の単球系細胞U937において、タバコ抽出液曝露にてPSRの発現が増強することを示した。このPSR発現はVascular endothelial growth factor(VEGF)receptor blockerであるSU5416により濃度依存性に抑制された。このことはマクロファージのアポトーシス細胞貪食能にVEGFがPSR発現を介して間接的に関与していることを示唆する。
    日本学術振興会, 基盤研究(C), 北海道大学, 20590890
  • 難治性気道疾患への新たな挑戦-病態、診断、治療へのアプローチ-
    科学研究費助成事業
    2007年 - 2008年
    西村 正治, 桧澤 伸之, 別役 智子, 南須原 康行
    難治性の気道疾患という観点から慢性閉塞性肺疾患(Chronic obstructive pulmonary disease : COPD)と気管支喘息をとらえ、その克服をめざしたものである。近年、酸化ストレスが、COPD、気管支喘息の病態に様々な形で関与すると考えられており、具体的には1)治療標的の特定を目指す病態の解明、2)低侵襲的気道病態の評価法の開発(新規酸化ストレスバイオマーカー・3次元的気道画像解析)、3)抗酸化剤治療介入へ向けての基礎的研究、4)北海道COPDコホート研究という4つのプロジェクトからなる。
    日本学術振興会, 基盤研究(B), 北海道大学, 19390221
  • 3次元CTによる気腫・気道病変の評価と慢性閉塞性肺疾患病態解析への応用
    科学研究費助成事業
    2005年 - 2006年
    西村 正治, 南須原 康行, 小野寺 裕也
    今年度は、3次元画像解析を用いて、以下の3つの検討を行い結果を得た。1)以前から検討してきた右上葉肺尖枝B1と下葉前下行枝B8の2本の気管支に加えて、各部位より複数の枝(上葉3本、中葉2本、下葉3本)を測定し、COPD患者における気道病変の均一性の検討を行った。測定評価については、昨年度と同様に3次から6次分枝にかけて中枢から末梢にかけて気道の壁面積比(WA%)を検討した。多くの気管支を調べた結果、末梢の6次では中枢の3次に比べてlobeによるばらつきが少なく、我々が今まで検討していたB1,8の2本が特に末梢の6次に関しては他の気管支の6次の病変を十分に反映しているものと考えられた。2)-950HUを閾値にして気腫病変を立体的に定量評価し、さらに気腫病変を上肺、中肺、下肺と分割することにより、COPDにおける局所における気腫病変と気流制限および気道病変の関係について検討を行った。気流制限の程度は、上肺の気腫とは全く相関は見られなかったが、下肺の気腫とは強い相関が見られた。一方、上肺の気腫は同じく上肺の気道病変とは相関が見られなかったが、下肺の気腫と下肺の末梢気道病変に相関が見られ、下肺の気腫病変の進展と末梢気道病変の進行は、パラレルに進むことが考えられた。3)COPDにおける、気管支拡張薬(チオトロピウム)の気道への影響を3次元画像解析にて検討した。吸入による気流制限の改善の程度は、全体として気道内腔面積の改善の程度と相関し、その関係は3次、4次よりも5次、6次といったより末梢の気道内腔面積の改善と強い相関が見られた。
    日本学術振興会, 萌芽研究, 北海道大学, 17659242
  • 肺上皮障害・再生におけるbasigin/EMMPRINの役割とMMP誘導機序
    科学研究費助成事業
    2005年 - 2006年
    別役 智子, 南須原 康行
    線維化肺、肺がんにおけるbasigin/EMMPRINの役割を中心に検討した。当該施設にて肺がんと診断され手術を施行された患者、臨床的に間質性肺炎の診断がなされ、病理診断目的に胸腔鏡下肺生検を受けた患者を対象に。手術摘出された肺組織のホルマリン固定・パラフィン包埋薄切標本をmicrowave法で抗原賦活化後、抗ヒトEMMPRIN抗体(CHEMICON社,1000倍希釈)を1次抗体とし、Catalyzed Signal Amplification(CSA)法(DAKO社)を用いて免疫染色を施行した。basigin/EMMPRINによる誘導が報告されているMMP-1,-2,3-,-9についても連続切片で同様に免疫染色を施行した。また、以前、我々が作成したBAL液を用いた系を参考に、修正を加え測定方法を新たに確立し、同患者の血清やBAL液を用いて、basigin/EMMPRINの濃度をELISA法にて定量した。臨床的背景とその濃度との関係、病理組織上の免疫組織学的検討が可能である検体については、染色性との関係を明らかにした。以上の結果は、平成18年5月、米国胸部疾患学会にて報告し、Hum Patholに学術論文として掲載された。また、名古屋大学との共同研究において、basigin/EMMPRINのノックアウトマウスの供与を受け、気管支喘息モデルを作成している。ノックアウトマウスにおける気道炎症の程度、各種マトリックスメタロプロテアーゼの発現の有無を詳細に現在分析中である。本結果は、平成19年5月に米国胸部疾患学会にて発表予定である。一方、ラット肺気道上皮細胞を用いてbasigin/EMMPRIN遺伝子の誘導機序に関する検討を行った。基底膜構成成分のひとつであるlaminin-1がその誘導能を有することを明らかにした。一連の成果については、平成19年5月日本呼吸器学会におけるシンポジウム、ミニシンポジウム、また同年5月サンフランシスコで開かれる米国胸部疾患学会において多数の演題を発表予定である。
    日本学術振興会, 基盤研究(C), 北海道大学, 17590772
  • 慢性閉塞性肺疾患(COPD)の病因、病態、病型別自然歴に関する統合的研究
    科学研究費助成事業
    2005年 - 2006年
    西村 正治, 檜澤 伸之, 別役 智子, 南須原 康行, 小野寺 裕也
    本研究について、第二年度として、一定の成果をあげることができた。短期、長期喫煙暴露による肺障害マウスモデルを作成し、細気管支上皮における遺伝子発現のin vivoにおける経時的変化を定量することができた。特に、抗酸化能、解毒機構に関与する遺伝子群について、それらの網羅的解析による発現プロファイルと、DNA酸化、転写機構に関する知見を得た。我々は、喫煙の急性効果と慢性効果の気道上皮の反応性の違いを明らかにし、その機序を解明する研究に取り組んでいる。ヒトの手術肺を用いて、我々はCOPD病変に及ぼす加齢と喫煙の相補的影響を明らかにした。ヒトの肺検体から、laser capture microdissection (LCM)法を用いて、細気管支上皮を選択的に採取する方法を用いて、COPD患者において選択的に上昇・低下する遺伝子をスクリーニングした。細胞内過酸化水素に対して抗酸化機構に関与するカタラーゼ遺伝子に注目し、COPD患者の細気管支上皮、およびマクロファージにおいては、カタラーゼ遺伝子、蛋白の発現が低下していることを明らかにした。気管支鏡を用いて採取した末梢気道上皮細胞を用いる研究については、中枢気道上皮に発現するNADPH系oxidaseに注目した。喫煙刺激に対してDuox1hは低下し、逆にDuox2の発現が低下することを明らかにした。ex vivo環境下での機能保持、分化に及ぼす基底膜の立体構造の影響について研究中である。
    また、北海道COPDコホート調査として307名の登録を行った。その中で、52名のCOPD患者を対象として、気道の評価を行った。対象とした気管支は、右肺尖枝のB1と右前肺底枝のB8で、それぞれ3次分岐から6次分岐までの気道内腔面積(Ai)と気道の外周で囲まれた気道の総断面積に対する気道壁の割合(WA%)を測定した。B1の一部を除いて、Ai、WA%とも、対標準1秒量と有意な相関を示した(WA%は逆相関)。さらに、Ai、WA%とも、末梢の気管支ほど相関係数が大きかった。一連の成果については、平成19年5月日本呼吸器学会におけるシンポジウム、ミニシンポジウム、また同年5月サンフランシスコで開かれる米国胸部疾患学会において多数の演題を発表予定である。
    日本学術振興会, 基盤研究(B), 北海道大学, 17390239
  • 炎症性呼吸器疾患の内因に関する研究
    科学研究費助成事業
    2002年 - 2004年
    南須原 康行, 山口 悦郎, 檜澤 伸之, 別役 智子, 西村 正治, 南須原 康行
    ・本研究では、日本人において喘息発症に影響を与える遺伝因子を検討するために、包括的遺伝子発現解析から喘息病態との関連が大きいと考えられるいくつかの候補遺伝子に着目し、それらの遺伝子に存在する機能的な遺伝子変異の喘息発症における意義を検討した。検討した遺伝子は高親和性IgE受容体β鎖遺伝子(FCER1B、11q13)、プラスミノーゲンアクチベーターインヒビター遺伝子(PAI1、7q21)である。気管支喘息患者(約400名)、健常人(約400名)を対象とした。FCER1B遺伝子の-109C/T多型は喘息患者における血清総IgE値に遺伝的な影響を与えていた。FCER1B遺伝子とPAI1遺伝子いずれの多型も単独では気管支喘息との間に関連を認めなかったが、FCER1B遺伝子がTT型の場合にはPAI1遺伝子5G5G型が4G型を有する遺伝子型(4G4G or 4G5G)に比べ有意に喘息発症のリスクが小さかった。これらの一連の研究結果は、検討したそれぞれの分子の喘息病態における重要性を遺伝疫学的な手法で確認したことに加え、FCER1BとPAI1との交互作用の存在から、これらの分子を内包した共通のpasswayの存在と、それらの喘息病態における重要性を示したことに意義がある。
    ・肺気腫に関しては、laser capture microdissection (LCM)法とRT-PCR法を用いて末梢気道上皮細胞および肺内マクロファージにおける3種類のケモカインの発現を定量し、喫煙、COPDの病態との関連を検討した。対象は肺癌にて肺葉切除術を受けた喫煙歴のない患者10名、喫煙歴があるが閉塞性障害や気腫病変を有さない患者10名。喫煙歴があり閉塞性障害あるいはCT上気腫性病変を有する患者10名。非癌部肺組織の凍結標本からLCMにて末梢気道上皮細胞およびマクロファージを選択的に採取した。閉塞性障害あるいはCT上気腫性病変を有する患者では、末梢気道上皮細胞におけるIL-8,MIP-1α,MCP-1の発現が他の2群に比べ有意に高かった。肺内マクロファージにおいては喫煙歴や疾患によるケモカイン発現に差は認められなかった。末梢気道上皮における炎症性ケモカインの産生亢進が、肺気腫の病態に関与している可能性を示唆する。
    日本学術振興会, 基盤研究(B), 北海道大学, 14370193
  • 難治性気管支喘息の病因解明と抗マクロファージ遊走阻止因子抗体による治療の試み
    科学研究費助成事業
    2000年 - 2001年
    西村 正治, 南須原 康行, 西平 順
    ・抗MIF抗体のアトピー型気管支喘息モデルに対する効果
    昨年度は,BNラットを卵白アルブミンで感作したアトピー型気管支喘息モデルにおいて,1)吸入誘発後の肺胞洗浄液中のMIF濃度は,未処置群に比して有意に上昇していた,2)坑MIF抗体は卵白アルブミンによる特異的気道収縮を著明に抑制した.3)抗MIF抗体は肺胞洗浄液中の総細胞数はを有意に減少した,その分画の検討において,この減少は主に好酸球と好中球の減少によることが判明した,4)感作ラットでは卵白アルブミンに対する特異的IgGが上昇するが,抗MIF抗体はその上昇には影響を与えなかった,との結果を得た.これらの結果より,抗MIF抗体はアトピー型喘息モデルにおいて,特異的IgEの産生には影響を与えないが,特異的気道収縮および気道炎症を抑制することが示唆された.
    今年度はさらに,
    1)抗MIF抗体は,メサコリンに対する気道反応つまり非特異的気道収縮を抑制した.
    2)吸入後の肺組織を用いて,定量的real time PCR法により,好酸球の走化因子であるエオタキシンの発現を検討した結果,抗MIF抗体はエオタキシンの発現を抑制した.
    との結果を得た.現在,好中球の走化因子であるCINCについて肺胞洗浄液を用いて,抗MIF抗体の効果を検討中である.さらに,今後は肺組織標本を用いて,MIF発現部位,時間的推移などについて更なる検討を加える予定である.
    日本学術振興会, 萌芽的研究, 北海道大学, 12877091
  • 染色体5q31および11q13のIgE高反応性遺伝子の同定
    科学研究費助成事業
    1998年 - 2000年
    山口 悦朗, 川上 義和, 南須原 康行, 伊藤 昭英, 山口 悦郎, 棟方 充
    (1)我々は高親和性IgEFc受容体遺伝子(FceRIb)のプロモーター領域-109の位置に新たにCからTへの1塩基置換を発見した。この多型の分布は喘息と健常人の両群で特に有意な差は認められなかったが、喘息群において対立遺伝子Tをホモで有する喘息患者は、それ以外の遺伝子型(TCまたはCC)を有する喘息患者に比べて有意に血清総IgEが高い値を示した(p=0.0015)。また喘息の発症年齢を考慮して同様の検討を行うと、遺伝子多型の総IgE値への影響がより明瞭に認められた(p=0.0004)。
    (2)我々はまたIL-4非翻訳部位に新たな多型(+33C/T)を発見した。T対立遺伝子頻度は喘息患者で0.675、健常者で0.671と両群に有意差を認めなかった。一方、遺伝子型(CT+TT)はCCに比して、検討対象者全員および喘息群において、性、年齢で補正しても有意に血清総IgE値が高かった。
    (3)上記二つの1塩基多型(SNP)について、血清総IgE値におよぼす相互作用を検討した。その結果、喘息患者において両SNPが、血清総IgE値に及ぼす影響は、お互いの遺伝子型に依存する可能性が示唆された。
    (4)アトピー性皮膚炎群での上記二つのSNP頻度は健常群と比べ有意差は認められず、これらの遺伝子多型はアトピー性皮膚炎の発症に寄与していないと考えられた。また両SNPはアトピー性皮膚炎での血清総IgE値と相関を示さなかった。したがって、アトピー性皮膚炎のIgE上昇の個体差には、高親和性IgE受容体β鎖遺伝子やIL-4遺伝子より、むしろ他の遺伝子多型あるいは環境因子の関与が大きいと考えられた。
    (5)ムスカリンM1受容体遺伝子の翻訳開始部位からそれぞれ287bpと1353bp下流の位置にアミノ酸置換を伴わない1塩基多型を発見した。同多型に関する症例対照研究では、健常対照群に比べ喘息群では遺伝子型CCの頻度が有意に高く、M1受容体遺伝子はアトピーとは独立して喘息の発症に影響を与えている可能性がある。
    日本学術振興会, 基盤研究(A), 北海道大学, 10307013
  • 特発性間質性肺炎の進展予防               
    競争的資金

担当教育組織